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CHAPTER 1 
Introduction 
Hypertension, defined as blood pressure ≥ 140/90mmHg, is a worldwide health concern that 
affects approximately 30% of adults and 70% of the elderly in the United States. Hypertension 
contributes to cardiovascular disease morbidity and mortality [1]. In 2010 it was ranked as the 
top single risk factor for global burden of disease and affects individuals in both economically 
developed and developing nations alike [2]. End-organ damage of the kidneys and vasculature 
are important manifestations of the disease. As such, those who suffer from hypertension are 
more likely to develop atherosclerosis, stroke, myocardial infarction, heart failure, chronic 
kidney disease and dementia [1, 3]. While occasional cases of hypertension are due to 
identifiable causes, such as renal artery stenosis, pheochromocytoma, excessive adrenal 
aldosterone production, or monogenetic causes, more than 90% of cases do not have an 
identifiable etiology and are classified as “essential”. Essential hypertension often co-exists with 
obesity, disorders of lipid metabolism, aging and insulin resistance, and thus is often considered 
as part of a complex metabolic phenotype that has myriad manifestations [4].  
Classic Concepts of Hypertension 
Perturbations of the vasculature, central nervous system and the kidneys have all been implicated 
in essential hypertension, and likely all contribute to elevations of blood pressure. Yet, the 
precise manner in which these systems are recruited and interact remains undefined. Blood 
pressure is the product of cardiac output and systemic vascular resistance. Thus, either cardiac 
output or systemic vascular resistance must be elevated in chronic hypertension. Interestingly, it 
appears these play different roles depending on age and duration of hypertension. Fagard and 
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Stassen measured cardiac output at rest and during exercise in 110 hypertensive individuals 
ranging from 16 to 64 years of age, and found that cardiac output is elevated in younger 
individuals (<age 25) with hypertension but was within the normal range in older patients [5]. 
While this might reflect differences in the etiology of hypertension in younger vs older 
individuals, this pattern is compatible with the concept that blood volume, and thus cardiac 
output is elevated early in hypertension, and that there are vascular adaptations that occur later in 
the disease, associated with a reduction in blood volume, and an increase in systemic vascular 
resistance.  
Why would blood volume be increased in hypertension? There is substantial support for the 
concept that renal retention of volume and sodium must occur to sustain hypertension; simply 
stated, in the setting of normal kidneys, an increase in blood volume and elevation of blood 
pressure leads to a brisk diuresis and ultimately the normalization of blood pressure. The 
relationship between blood pressure with sodium and water excretion can be described by the 
‘pressure-natriuresis’ relationship defined by Guyton and co-workers. For hypertension to be 
sustained there must be a rightward shift in this relationship. Any insult or change to the kidney 
that alters this ability to excrete sodium and water will result in a ‘natriuretic handicap;’ wherein 
the mean arterial pressure over which salt and water is excreted will increase to account for a 
decrease in the capacity of kidney function [6]. This is often not reflected by overt changes in 
renal function, but by enhanced reabsorption of sodium and water along the nephron regulated 
through differential activity of the various proximal and distal transporters. Sustained 
hypertension is associated with vascular rarefaction within the kidney, fibrotic replacement of 
renal parenchymal tissue, and defects in glomerular function and proteinuria [7, 8]. These defects 
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in renal function underlie the importance of sodium restriction and use of diuretics in the 
treatment of hypertension, which act in part to normalize the pressure natriuresis curve. 
If blood volume is increased in early hypertension, or in younger age groups, why does it return 
to normal values with time and why is there a concomitant increase in systemic vascular 
resistance? Guyton proposed that the increase in cardiac output would lead to “systemic 
autoregulation”, and that this further raises blood pressure, leading to a pressure natriuresis and 
return of blood volume (and cardiac output) to near normal levels. It is now clear that 
hypertension is associated with other events that increase systemic vascular resistance. These 
events evolve slowly [9, 10]. These include enhanced vasoconstriction due to factors including 
loss of endothelium-derived nitric oxide, local production of potent vasoconstrictors such as 
endothelin-1, prostaglandin H2, and angiotensin II (Ang II), and increased production of reactive 
oxygen species (ROS), such as superoxide. There is also remodeling of vessels in hypertension, 
initially described by Folkow, in which the vascular lumen is narrowed as the media thickens 
[11]. Finally, there is frank loss of capillaries and resistance vessels, known as vascular 
rarefaction, in hypertension. All of these events combine to reduce the cross sectional area of the 
vasculature and predispose individuals to increased systemic vascular resistance and 
hypertension [12, 13].  
How does the central nervous system contribute? Activation of the sympathetic nervous system 
results in release of norepinephrine from postganglionic neurons which act through adrenergic 
receptors on target organs. Increased sympathetic outflow and adrenergic agonists contribute to 
left-ventricular hypertrophy, vascular remodeling and vascular smooth muscle cell proliferation 
[14]. Furthermore, the sympathetic nervous system innervates renal tubules, renal vessels and the 
juxtaglomerular granular (JG) cells of the kidney. Not only does enhanced renal sympathetic 
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nerve activity result in increased sodium and water reabsorption in the nephron and constriction 
of the renal vasculature, increased renal sympathetic nerve activity stimulates renin release from 
JG cells creating a feed-forward mechanism that activates the renin-angiotensin (RAS) system. 
These changes magnify the activity of renal transporters further increasing sodium and water 
reabsorption and promoting hypertension [15]. 
Emerging evidence over the past decade suggests that these alterations stem from, at least in part, 
an underlying inflammatory condition during which innate and adaptive immune cells become 
activated, invade target tissues and promote end-organ damage through production of various 
cytokines and chemokines.  
Rodent Models of Hypertension 
Several different rodent models are commonly used to experimentally induce and study 
hypertension. One of these methods is the infusion of Ang II into mice or rats. As described 
above, Ang II is a hormone responsible for stimulating many effects that lead to hypertension. 
Ang II is infused into rodents via osmotic mini pumps at pressor doses of either 490 or 1000 
ng/kg/min over the course of, commonly, 7,14 or 28 days [16, 17]. A second method, the 
deoxycorticosterone acetate (DOCA) /salt method, results in induction of a salt sensitive form of 
hypertension [18, 19]. Salt sensitivity is defined as >5-10% change in blood pressure with salt 
intake [20]. In this case, investigators remove one kidney, implant a DOCA pellet, and feed the 
mice or rats 1% salt water over the course of 3 weeks. DOCA is an aldosterone analog and thus 
results in increased sodium and water reabsorption in the kidney. Another salt-sensitive model is 
the L-NG-Nitroarginine Methyl Ester (L-NAME) and high salt method for inducing 
hypertension. In this case animals are initially given L-NAME in the drinking water for two 
weeks; they then go through a two week washout period and subsequently receive a 4%NaCl 
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high salt diet for the next three weeks [21]. Genetic adaptations that predispose rats to 
hypertension are also commonly studied. One such rat is the spontaneously hypertensive rat 
(SHR). These rats were generated by Okamoto and colleagues who bred a male Wistar Kyoto rat 
with noticeably elevated blood pressure to a female Wistar Kyoto rat with slightly elevated blood 
pressure in the 1960s [22]. The development of hypertension in the SHR begins at about 5-6 
weeks of age. Another rat strain genetically prone to develop hypertension is the Dahl Salt-
Sensitive rat. In the 1960s as well, Lewis K. Dahl began breeding rats together that were 
susceptible to the effects of a high salt (8% salt) diet, i.e. they developed hypertension and its 
accompanying comorbidities [23]. Today this strain is still used to investigate mechanisms of 
salt-sensitive hypertension. 
Brief History of the Immune System in Hypertension 
The idea that the immune system plays a role in hypertension was first proposed in the 1960s. 
Grollman et al. showed that the transfer of lymphocytes from rats that had induced unilateral 
renal infarction to previously normotensive rats caused hypertension in the recipients [24]. 
Additionally, Grollman et al. demonstrated that immunosuppression lowers blood pressure in 
rats that had partial renal infarction [25]. Olsen et al. described an inflammatory reaction 
occurring inside the vasculature of humans with different causes of hypertension; specifically he 
noted a periadventitial accumulation of T cells and monocytic cells [26]. 
In the 1970s Svendsen discovered that mice which were thymectomized or athymic nude mice 
do not maintain hypertension post renal infarction [27]. Ba et al., in the 1980s, discovered that 
transplant of a thymus from a Wistar-Kyoto (WKY)  reduced blood pressure in a recipient 
spontaneously hypertensive rat (SHR). They also noted that transplanting a compatible thymus 
into neonatal SHRs resulted in significant suppression of blood pressure if full immunologic 
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restoration was achieved [28]. These experiments set the stage for recent advances regarding the 
role of the immune system in hypertension. 
Innate Immune System and Hypertension 
The innate immune system is responsible for the non-specific early response to antigen that 
occurs in the body and also for priming the adaptive immune system to said antigen which it 
subsequently attacks with a specific response. One of the first cell types of the innate immune 
system formally associated with the development of hypertension was the monocyte. Monocytes 
are antigen presenting cells (APCs). APCs are specialized cells which present antigen to and thus 
activate the adaptive immune system. APCs are also composed of macrophages and dendritic 
cells (DCs). One of the first studies to clarify the importance of monocytes to the development of 
Ang II-induced hypertension was performed by Wenzel et al. The authors selectively depleted 
monocytes in mice by treating animals that had inducible expression of the diphtheria toxin 
receptor on myeloid cells (LysMiDTR) with a low dose regimen of the toxin. Depletion of 
monocytes blunted hypertension and attenuated endothelial dysfunction, a condition resulting in 
imbalanced levels of vasodilating and vasoconstricting substances in the vessels leading to 
increased vasoconstriction and systemic resistance during hypertension, relative to controls. The 
hypertensive response was fully restored by adoptive transfer of wild type monocytes into 
depleted mice [29]. 
Our laboratory and others have shown that immune cells infiltrate the kidney and perivascular fat 
of vessels and release cytokines that alter organ function. Infiltrating APCs, including monocytes 
and DCs, contain multiple important sensors of the innate immune system allowing them to 
respond appropriately to pathogens; one of these sensors is the inflammasome. Inflammasomes 
are complexes activated by different pathogen- and danger- associated molecular patterns 
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(PAMPs and DAMPs) which lead to the cleavage of IL-β and IL-18 inside the cell. These 
cytokines are subsequently released to activate pro-inflammatory signaling pathways. Of the 4 
inflammasome complexes that exist, the NLRP3 inflammasome reacts to multiple stimuli 
implicated in the pathogenesis of hypertension, including ROS and other molecules associated 
with stress and danger responses. Three recent studies have demonstrated the importance of the 
inflammasome to hypertension. Wang et al. showed that hypertension is blunted in 
inflammasome-deficient ASC-/- and NLRP3-/- mice using a renin-dependent model of 
hypertension [30]. ASC is an adaptor protein crucial to formation of an active inflammasome 
complex. Krishnan et al demonstrated that ASC-/- are protected from both the DOCA/salt and 
Ang II-induced models of hypertension. These authors also demonstrate that a specific NLRP3 
inhibitor reverses DOCA/salt induced blood pressure increases, indicating a causal role for the 
inflammasome and its key cytokines, IL-1β and IL-18, in the development of hypertension [19]. 
While Bruder-Nascimento et al. report that long-term aldosterone infusion in mice results in 
increased plasma levels of IL-1β and increased vascular contractility coupled with decreased 
endothelial-dependent vascular relaxation in mesenteric arterioles. Mice that lacked either the IL-
1 receptor (IL-1R1) or NLRP3 and caspase 1, another important inflammasome component, were 
protected from those vascular abnormalities [31]. 
The demonstrated importance of IL-β to the development of both human and rodent hypertension 
led Zhang et al. to investigate the effect of this cytokine on the kidney.  The authors recently 
showed that genetic deficiency or blockade of IL-1R1 limited the extent to which blood pressure 
could rise in response to Ang II infusion, adding to previous evidence implicating IL-1 signaling 
in the pathogenesis of hypertension. Furthermore, they went on to demonstrate that signaling of 
the IL-1R1 in the kidney prevents intra-renal myeloid cells from maturing into Ly6C+Ly6G+ 
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macrophages which produce nitric oxide (NO). NO is a known suppressor of Na-K-Cl 
cotransporter 2 (NKCC2). Thus, IL-1R1 signaling effectively activates NKCC2 in the kidney, 
promoting sodium reabsorption and blood pressure elevation [32]. 
Additionally, innate immune cells such as monocytes, macrophages and neutrophils contain 
functional NADPH oxidases which produce ROS to help eliminate invading pathogens. We have 
consistently found increased levels of ROS in the vasculature in models of hypertension [17, 33, 
34]. Therefore, activated innate immune cells in hypertension also contribute to vasoconstriction 
and vascular remodeling through production of ROS which lowers bioavailability of NO. 
The complement system is another important component of the innate immune system and 
functions to boost the abilities of antibodies and phagocytic cells to clear pathogens. Activation 
of this system leads to cleavage of the complement proteins, which are constantly in circulation, 
to their active state. The role of one such protein, anaphylatoxin C5a, in hypertension was 
recently examined by Weiss et al. The authors found that a majority of C5aR1 positive cells in 
the kidney were DCs and that renal injury, but not cardiac injury, after unilateral nephrectomy 
and Ang II infusion was ameliorated in mice lacking C5aR1  [35]. Thus the authors described a 
previously undefined role for C5a in the development of renal injury during hypertension. 
Shah et al. identified a population of myeloid-derived suppressor cells (MDSCs), which are 
immature myeloid cells capable of regulating and suppressing the immune system, that are 
increased in the circulation, the kidneys, and the spleen of hypertensive mice. These cells are 
capable of suppressing T cell proliferation and accumulate in the spleen where they interact with 
T cells in attempts to counter inflammation and blood pressure increase. The authors demonstrate 
that depletion of these cells results in an enhanced pro-inflammatory phenotype of T cells in both 
the spleen and kidney [36]. MDSCs were initially identified in cancer models and their 
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accumulation during chronic hypertension increases the evidence indicating that inflammatory 
and immune responses are dysregulated in this disease. 
Furthermore, our laboratory has recently identified the key cells that produce collagen and 
contribute to vascular stiffening in hypertension. The Harrison lab found that cells expressing 
stem cell antigen 1 (Sca-1) produce large amounts of collagen and take on a fibroblast like 
phenotype in hypertension. Additionally they found that the majority of cells producing collagen 
in the aorta during hypertension are bone-marrow derived [37]. This study thus identifies the 
bulk of collagen producing cells in the aorta as part of the innate immune system. 
T cells and Hypertension 
In 2007, our group showed that mice deficient in T and B cells (Rag1-/- mice) develop blunted 
hypertension and have preserved vascular endothelial function when infused with Ang II or 
DOCA/salt. Interestingly, adoptive transfer of T, but not B, cells restored the hypertensive 
response. Following Ang II infusion, T cells were shown to have become activated and to have 
infiltrated the perivascular adipose tissue of mice [38]. This paper was the first to directly link T 
cells to hypertension. 
Two important studies went on to confirm and expand upon the initial findings observed by our 
group regarding the importance of T cells to the genesis of hypertension. Mattson et al. generated 
Rag1-/- rats from the Dahl salt sensitive (SS) strain and found that blood pressure increase was 
blunted in Rag1-/- rats compared to wild type Dahl SS rats after high salt feeding. Rag1-/- rats had 
less immune cells accumulate in their kidneys after high salt feeding and also had attenuated 
glomerular and tubular damage compared to Dahl SS rats [39]. Crowley et al. described how scid 
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mice, which lack lymphocyte activity, develop blunted hypertension and cardiac hypertrophy 
when infused with Ang II [40]. 
Furthermore, Rudemiller et al. specifically investigated the role of the CD3 zeta chain (CD247), 
a gene important for T cell signaling, in hypertension. The authors deleted CD247 in Dahl SS 
rats using zinc-finger nucleases.  This deletion resulted in decreased infiltration of T cells into 
the kidney, lower blood pressure and preserved renal integrity in response to salt [41]. In general, 
T cell survival is dependent on functionality of Axl, a receptor tyrosine kinase. Axl has been 
linked to hypertension by several recent GWAS and genomic studies [42]. Batchu et al. 
demonstrate that Rag1-/- mice that received Axl-/- CD4+ T cells through adoptive transfer 
developed a blunted blood pressure increase and decreased perivascular adventitial T cell 
infiltration in response to DOCA/salt induction compared to those animals who received Axl+/+ 
CD4+ T cells. The authors report that the protective phenotype of Axl-/- CD4+ T cells is due to 
their inability to expand and survive after transfer, a function of Axl [43]. Together, these studies 
suggest that fully functional T cells are important for the development of hypertension and add 
more evidence demonstrating the need for these cells for disease progression.  
T cell Activation in Hypertension 
With verification of T cell involvement in hypertensive development, investigators became 
curious as to how these cells were being activated during disease progression. One possibility 
was with involvement of the sympathetic nervous system. To determine if sympathetic outflow 
and the activation of the sympathetic nervous system could be involved in immune activation, 
Marvar et al. looked at a specific region in the circumventricular organs (CVO) implicated in 
blood pressure control, the anteroventral third ventricle (AV3V) region. Previous research has 
shown that electrolytic lesions which disrupt the AV3V region completely eliminate the central 
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actions of Ang II. When the authors investigated T cell activation and vascular inflammation in 
mice which have AV3V lesions, they found that the blood pressure increase and activation and 
infiltration of T cells were virtually abolished in these mice in response to Ang II [44]. In 
relation, Xiao et al. recently investigated the importance of sympathetically innervated renal 
nerves, which transmit sympathetic outflow to the kidneys, to the development of hypertension 
using renal denervation. The authors found that bilateral renal denervation prevents dendritic cell 
(DC) activation. This resulted in less T cell activation and infiltration, a blunted blood pressure 
increase, and preserved renal integrity in response to Ang II [45]. Furthermore, Carnevale et al. 
recently showed that hypertensive stimuli trigger splenic sympathetic nerve discharge, a response 
that is necessary for T cell activation and their subsequent egression from the spleen during 
hypertension [46]. Together, these studies implicate the central nervous system and sympathetic 
outflow as important for T cell activation and hypertension.  
The CVO has also been shown to produce superoxide in response to Ang II. ROS have been 
linked to hypertension; therefore, Lob et al. investigated the effects of superoxide production in 
the CVO to T cell activation in hypertension in two studies. In the first, the authors deleted 
extracellular superoxide dismutase (SOD3) in the CVO of mice using an adenovirus encoding 
cre-recombinase/loxP based system. They found that deletion of SOD3 in the CVO results in 
enhanced T cell activation and vascular infiltration in response to Ang II. Moreover, they also 
found that the sympathetic modulation of the heart was increased. These studies suggest that 
superoxide production in the CVO may activate T cells through modulation of sympathetic 
outflow [47].  In the second set of studies, our laboratory implicated ROS production by the 
NADPH oxidases of the subfornical organ of the CVO as a crucial determinant in blood pressure 
regulation. Lob et al., again using an adenovirus encoding cre-recombinase/loxP system, deleted 
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the p22phox subunit of the NADPH oxidase in the SFO. This deletion prevented blood pressure 
increase and eliminated vascular inflammation and T cell infiltration in these mice in response to 
Ang II, adding further evidence to the importance of ROS signaling in the CVO to T cell 
activation in hypertension [48]. 
Traditionally, monocytes transverse the endothelium and differentiate into macrophages or DCs 
that function during disease. These activated APCs then migrate to secondary lymphoid organs 
where they come in contact with and activate T cells. In 2014, our laboratory described the 
importance of DCs to the activation of T cells during hypertension. Kirabo et al. showed that 
DCs in mice infused with Ang II become activated and produce increased amounts of ROS, 
ultimately leading to the production of isoketal-adducted proteins in these cells. These 
isoketalated proteins are then presented to T cells and promote their proliferation and 
differentiation [34]. Furthermore, overexpression of the NADPH subunit p22phox in vascular 
smooth muscle cells in mice resulted in their development of age-related hypertension, 
inflammation, and aortic stiffening due to increased production of ROS throughout their lifetime. 
Aortic stiffening is characteristic of aging and is a condition hallmarked by increased collagen 
deposition and a reduction in aortic compliance. At younger ages and among those not afflicted 
by cardiovascular disease, the elastic properties of the aorta allow it to act as both a supplier and 
reservoir of peripheral blood. Half of the blood is ejected during systole and as the aorta recoils 
during diastole the remaining blood is pushed into circulation to keep the body adequately 
perfused between heart beats, this is termed the Windkessel effect. Thus, accumulation of 
collagen or degradation of elastin results in a decrease in flexibility of the aorta and requires 
higher pressures to force blood into circulation [49, 50]. Wu et al. ultimately found that DCs 
isolated from these aged mice contain isoketalated proteins and that treatment with the 
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scavenger, 2-hydroxybenzylamine (2-HOBA), ameliorates age-dependent hypertension, 
inflammation and end-organ damage [51]. Together, these studies demonstrate the importance of 
ROS to isoketalated protein production, T cell activation and hypertension. 
Recently, studies have also linked gut microbiota to immune activation in hypertension. The 
human microbiome is dominated primarily by the species Firmicutes and Bacteroidetes, 
although, both the Actinobacteria and Proteobacteria are also present [52]. The gut microbiota 
can regulate up to 10% of the host’s transcriptome, including genes related to immunity [53, 54]. 
Cotillard et al. have shown that a decrease in microbial gene richness can result in low-grade 
inflammation [55]. Yang et al investigated the composition of the microbiota from fecal samples 
taken from the SHR, Ang II-induced hypertensive rats, and from humans with essential 
hypertension. The authors observed gut dysbiosis, or decrease in microbial richness, and an 
increased Firmicutes/Bacteroidetes ratio in all hypertensive models investigated. Oral 
administration of minocycline into Ang II infused rats normalized the Firmicutes/Bacteroidetes 
ratio and also attenuated blood pressure, thus connecting gut dysbiosis to activation of the 
immune system and to hypertension [56]. Furthermore, investigators have observed differences 
in the gut microbiota between the Dahl Salt-Sensitive and Dahl Salt-Resistant rats, thus adding 
further evidence implicating differences in microbiota to immune activation, inflammation and 
hypertension, although no direct mechanism has yet been identified [57]. Moreover, Santisteban 
et al. show that both SHR and Ang II-infused rats develop changes in their gut pathology; such 
as increases in their intestinal permeability. These alterations were associated with changes in gut 
microbial communities relevant to control of blood pressure in these animals. These authors also 
report an overall increase in sympathetic drive to the gut in these hypertensive animals, 
suggesting that abnormal sympathetic stimulation of the gut could drive changes in gut 
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pathology and gut microbial communities contributing to inflammation resulting in immune cell 
activation and hypertension [58]. 
T cell Subtypes in Hypertension 
α/β T cells are produced in the bone marrow and migrate to the thymus where they undergo 
negative and positive selection to determine which subtype, either CD4+ or CD8+, they will 
become. We investigated the role of both of these subtypes of T cells in hypertension and 
observed oligoclonal expansion of CD8+, but not CD4+, T cells in the kidney. Additionally, CD8-
/- mice developed blunted hypertension and preserved kidney and vascular function compared to 
CD4-/- mice [59]. These data demonstrate that an oligoclonal population of CD8+ cells in the 
kidney serve to drive the development of hypertension and are most important to the disease. 
However, CD4+ T cells produce cytokines, such as IL-17A and others, which are also important 
to disease pathogenesis. 
CD4+ T cells are able to differentiate into different subtypes relative to type of infection present 
or type of response needed (Figure 1-1, [60]). Characterization of the importance of each 
individual T cell subset in hypertension could shed light on potential therapeutic opportunities. 
Th1 cells are characterized by their expression of the transcription factor Tbet and by their 
production of large amounts of the cytokine, interferon-γ (IFNγ). Our laboratory found an 
increase in both CD4+ T cells and CD8+ T cells producing IFNγ in Ang II-induced hypertension, 
showing the importance of this T cell subset and of IFNγ to the development of the disease [17].  
The heart itself is also an important target of activated immune cells during hypertension. Marko 
et al. have shown that cardiac damage, measured by hypertrophy and fibrosis, and also cardiac 
inflammation were reduced in IFN-γ receptor (IFN-γR) knockout mice in response to Ang II. 
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Figure 1-1. T helper subsets and their cytokines. T cells can differentiate into unique subsets 
specific to the insult that is occurring (Bailey et al.) [60].  
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However, blood pressure was not changed in these mice. Furthermore, the authors reported that 
in relation to kidney function in IFN-γR knockout mice, their glomerular function was preserved, 
while general podocyte survival and functionality was impaired when the animals were exposed 
to a high dose of Ang II [61]. These results suggest that IFNγ signaling may be important for the 
function of podocytes. However, Zhang et al investigated IFNγ knockout mice but saw no 
change in blood pressure or albumin excretion [62]. 
In keeping with the above, we recently found that the adapter protein LNK (SH3B3) plays an 
important role in suppressing IFN-γ production and hypertension. T cells of mice lacking this 
protein were found to produce much greater levels of IFNγ than those of WT mice following 
infusion of Ang II. Notably, these animals exhibited a marked increase in inflammation during 
Ang II infusion, and this phenotype was transferable to WT mice by bone marrow transplant or 
adaptive transfer of LNK-deficient hematopoietic cells. These results indicate that LNK 
functions as a ‘brake’ to proliferation and cytokine signaling in hematopoietic cells in which it is 
expressed in the context of hypertension [17].  
Another important cytokine produced by Th1 cells is TNF-α. Zhang et al. show that TNF-α-/- 
mice develop blunted hypertension and end-organ damage in response to Ang II. The authors 
also demonstrate that TNF-α-/- mice had enhanced endothelial nitric oxide synthase (eNOS) 
expression and greater nitric oxide bioavailabilty than controls. These results suggest that TNFα 
signaling during hypertension limits eNOS expression and renal nitric oxide production. Zhang 
et al. also studied Tbet-/- mice and found that although blood pressure remained unchanged, 
nephrin elevation was blunted demonstrating preserved glomerular function [62]. Moreover, 
Chen et al investigated the effects of Angi II infusion on TNF-R1 (TNF-α receptor) deficient 
mice. Interestingly, TNF-R1-/- mice displayed increased blood pressure and albuminuria 
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compared to WT mice after 7 days of Ang II infusion. Additionally, the authors report that TNF-
R1-/- mice also have increased urinary TNF-α compared to WT mice after Ang II infusion. Thus, 
the authors proposed that TNF-α may normally modulate kidney responses to Ang II through 
TNF-R1 and therefore its deletion results in an exacerbated hypertensive phenotype [63]. 
Venegas-Pont et al. investigated the contribution of TNF-α to the development of hypertension 
that arises concomitantly in a genetic mouse model of systemic lupus erythematosus (SLE), a 
chronic inflammatory disease. The authors infused female SLE (NZBWF1) mice with 
etanercept, a TNF-α antagonist, or vehicle for 4 weeks. Excitingly, they observed that mean 
arterial pressure, albuminuria, monocyte/macrophage infiltration and renal cortex NADPH 
activity were reduced in SLE mice treated with etanercept compared to those given vehicle, thus 
confirming the importance of TNF-α in development of hypertension in the setting of a chronic 
inflammatory disease [64]. Taken together, these studies display a contribution of Th1 cells to 
hypertensive end-organ damage. 
In addition, the kidney has its own RAS system. Activation of the intrarenal RAS in the kidney 
contributes to the development of hypertension and also to kidney end-organ damage. A recent 
study by O’Leary et al. described how inflammatory cytokines contribute to the activation of 
intrarenal RAS. The authors found that IL-6, which is produced by monocytes and macrophages, 
through STAT3 activation, was responsible for elevation of angiotensinogen expression in 
proximal tubule cells [65]. Moreover, Satou et al had previously demonstrated how IFN-γ 
regulates angiotensinogen production by renal proximal tubule cells. Their studies showed that 
treatment of renal proximal tubular cells with IFN-γ for 6 or 12 hours results in a decrease of 
angiotensinogen production, however, 24 or 48 hours of exposure results in an increase in 
angiotensinogen production. They went on to discover, through RNA interference studies, that 
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this biphasic regulation of angiotensinogen is controlled in these cells by STAT1-SOCS1 axis 
modulation of STAT3 activity [66]. These studies highlight a potential mechanism by which 
IFN-γ modulates blood pressure. 
Hashmat et al. investigated the importance of IL-6 to the development of salt sensitive 
hypertension. They found that an IL-6 neutralizing antibody administered during the course of 
high salt feeding ameliorated blood pressure in Dahl salt-sensitive rats. The IL-6 antibody also 
reduced their urinary albumin excretion, glomerular damage and tubular damage. These 
investigators further showed that infiltration of monocytes and macrophages was significantly 
reduced by IL-6 blockade, implicating this cytokine in the pathogenesis of salt sensitive 
hypertension [67]. 
Th17 cells are characterized by their expression of the transcription factor retinoic acid receptor-
related orphan receptor gamma (RORγt) and of the cytokine IL-17A. Many studies have 
implicated Th17 cells in different autoimmune diseases. Madhur et al. observed that IL-17-/- mice 
do not sustain hypertension and are protected from T cell infiltration and vascular dysfunction 
caused by 4 weeks of Ang II compared to WT mice [33]. These studies were the first to show 
that signaling from IL-17 is necessary for the maintenance of hypertension. In a later set of 
studies, our laboratory confirmed the importance of IL-17A to hypertensive development 
through the use of antibody inhibition. Infusion of monoclonal antibodies to IL-17A or for its 
receptor, IL-17RA, during the second half of a 4 week Ang II infusion protocol in mice resulted 
in a reduction in blood pressure, a reduction in renal and vascular inflammation and blunted the 
development of albuminuria when compared to mice infused with control antibodies. These data 
suggest that IL-17A antibodies could be a useful treatment for hypertension [68]. 
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Amador et al. found activation of Th17 cells in both the heart and kidney of rats through 
measurements of IL-17 and RORγt after induction of DOCA/salt hypertension. Moreover, the 
authors also found that treating DOCA/salt rats with an anti-IL-17 antibody reduced blood 
pressure and reduced expression of many pro-inflammatory and pro-fibrotic mediators in both 
the heart and kidney [18]. These studies confirm the importance of IL-17 signaling to the 
development of hypertension. 
Our laboratory also investigated the importance of IL-17A to aortic stiffening in hypertension. 
We found that IL-17A-/- mice were protected against aortic stiffening [69]. Interestingly, Jiang et 
al. recently demonstrated the importance of IL-17A and Th17 cells to vascular remodeling 
during hypertension. The authors show that infusing mice with both Ang II and IFN-y results in 
decreased collagen 1 and III expression compared to mice only infused with Ang II. They also 
report a decrease in osteopontin expression in the spleen that coincides with reduced Th17 cell 
numbers in the spleen in the group that received both IFN-y and Ang II infusion compared to 
those just receiving Ang II [70]. Thus the authors conclude that IFN-y infusion may inhibit 
differentiation of CD4+ T cells to Th17 cells and also vascular remodeling during hypertension 
through modulation of osteopontin expression in the spleen. 
Our laboratory provided the first evidence specifically linking the pro-inflammatory cytokines, 
IFN-γ and IL-17A to activity of kidney transporters in 2015. Specifically, Kamat et al. observed 
preserved renal function measured by urinary sodium excretion in response to a saline challenge 
in IFN-γ-/- mice but not WT mice after 2 weeks of Ang II infusion. This may, in part, be 
explained by a demonstrated decrease in expression of the distal transporters NKCC2 and Na-Cl 
cotransporter (NCC) coupled with maintenance of pressure natriuresis along the proximal tubule, 
measured by an expected decrease in sodium and hydrogen exchanger 3 (NHE3) expression, in 
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IFN-γ-/- mice but not in WT mice after 2 weeks of Ang II infusion. Furthermore, IL-17A-/- mice 
also display preserved renal function measured by urinary sodium excretion in response to a 
sodium challenge along with maintenance of the pressure natriuretic response, thus reduction in 
NHE3 expression, after 2 weeks of Ang II infusion compared to WT mice. However, distal 
tubular transporter expression is not changed compared to WT after 2 weeks of Ang II infusion 
[71]. These studies demonstrate the importance of both IFN-y and IL-17A to hypertension 
through their effects resulting in the reabsorption of sodium and water and thus elevated blood 
pressure. 
However, one may question the potential molecular mechanism through which IL-17A and IFN-
y act in the kidney cells themselves to cause these effects. To understand the mechanism through 
which IL-17A acts in the kidney we examined the profile of sodium transporters in the kidneys 
of WT and IL-17A-/- mice following 4 weeks of Ang II infusion. In WT mice, Ang II infusion 
caused an almost 2-fold increase in expression of both NCC and the epithelial sodium channel 
(ENaC), relative to sham. In striking contrast, there was no Ang II-induced increase of NCC or 
ENaC in IL-17A deficient mice. Additionally, we found that serum and glucocorticoid-regulated 
kinase 1 (SGK1) mRNA expression increases in the kidneys of WT mice after both 2 and 4 
weeks of Ang II infusion, and that this increase was absent in the IL-17A deficient animals. In 
vitro studies revealed an SGK1 dependent increase in NCC activity in mouse distal convoluted 
tubule cells (mDCT15) and also an SGK1 dependent increase in NHE3 protein expression in 
human proximal tubule kidney epithelial cells (HK-2). Furthermore, IL-17A-/-  mice were 
protected from renal injury that results from angiotensin II infusion, measured through 
albuminuria and angiotensinogen abundance in the urine [16]. These studies provide insight into 
how one inflammatory cytokine, IL-17A, can regulate sodium and water balance in the kidney.  
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Large amounts of evidence have demonstrated that T cells in hypertension predominantly 
infiltrate the perivascular adipose tissue and adventitia of vessels to exert their effects.  A recent 
study performed by Mikolajczyk et al. demonstrates that this is effect is, in part, due to the 
chemokine RANTES (CCL5). Many of the cells, importantly T cells, which infiltrate the 
perivascular adipose tissue, bear the RANTES receptor CCR5. The authors show that vascular 
accumulation of IFN-y producing T cells and macrophages and also endothelial dysfunction are 
blunted in RANTES-/- mice infused with Ang II [72]. However, blood pressure is not decreased 
in these mice. This may be because deletion of RANTES does not affect kidney inflammation or 
dysfunction and because of the primary effects of Ang II itself. A later study performed by 
Rudemiller et al. detailed the protective effects of RANTES in the kidney. The authors show that 
RANTES deficient mice develop worse kidney damage and increased levels of macrophage 
infiltration into the kidney compared to controls in response to normotensive unilateral ureteral 
obstruction, a model of endogenous RAS activation. They go on to show that RANTES 
unexpectedly limits the pro-inflammatory actions of CCL2 in the injured kidney thereby 
restraining macrophage accumulation [73]. 
Anti-inflammatory T regulatory cells (T regs), characterized by their expression of the 
transcription factor forkhead box P3 (Foxp3) and of the cytokine IL-10, are capable of 
suppressing the immune response. These cells directly contribute to the maintenance of immune 
self-tolerance. Kvakan et al. show that adoptive transfer of T regs into Ang II infused mice 
results in less cardiac hypertrophy and fibrosis of the heart, despite no change in blood pressure. 
However, the authors do show reduced T cell infiltration into the hearts of animals that received 
T regs, displaying a critical role for T regs in suppression of the inflammatory response that 
results from Ang II infusion [74]. 
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Katsuki et al. found that lower numbers of T regs present is crucial for the development of 
hypertension in the stroke-prone spontaneously hypertensive rat (SHRSP). The authors also 
observed that a reduction in sympathetic outflow to the spleen via splenic denervation in pre-
hypertensive SHRSP rats increases numbers of T regs and delays the onset of hypertension in the 
rats, further implicating CNS control over T cell activation, differentiation and apoptosis in 
hypertension [75]. Viel et al found dysfunctional T regs in the Dahl SS rat.  When T regs from 
the Dahl SS rat were compared to Brown Norway rats, the suppressive capacity of T regs was 
impaired [76].  
Barhoumi et al. found that adoptive transfer of T regs into WT mice prevented Ang II- induced 
blood pressure increases and decreased Ang II-induced renal injury and immune cell infiltration. 
Additionally, the authors described an Ang II-induced decrease in Foxp3+ T reg cells in the 
kidney, which would thereby support an inflammatory phenotype in the kidneys in hypertension 
[77]. Several other groups have shown this as well. Matrougui et al. similarly saw a reduction in 
T regs in Ang II-infused mice. These authors also noted improved coronary arteriolar endothelial 
function in mice that received adoptive transfer of T regs [78]. Mian et al. demonstrate that 
microvascular injury, measured by examining microvascular remodeling and stiffness, was 
exaggerated in Rag1-/- given T cells from Scurfy mice compared to mice given WT T cells in 
response to Ang II. Scurfy mice are deficient in T regs because of their mutated Foxp3 gene [79]. 
Taken together, these data from mice and rats demonstrate that the presence of functional T regs 
are crucial for controlling the hypertensive response. 
A fundamental feature of adaptive immunity and of all T cell subtypes is their ability to form 
memory cells post antigenic exposure. Memory ensures a swift reactivation of the adaptive 
immune system in the event that the host sees the antigen at a later date. Memory T cells either 
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live in secondary lymphoid organs as central memory cells or in the periphery as effector 
memory cells. Our laboratory found that exposure to hypertensive stimuli results in the 
production of effector memory T cells that localize to the kidneys and to the bone marrow. These 
cells appear to be the major sources of IFN-y and IL-17A in the kidneys of hypertensive mice. It 
is appreciated that memory T cells are able to reside in the bone marrow long term in a quiescent 
state. We were able to demonstrate that repeated exposure to hypertensive stimuli after initial 
priming results in reactivation and migration of bone marrow residing memory T cells back to 
the kidney [21]. These data illustrate a previously undescribed role of memory T cells in 
hypertension. Interestingly, Olofsson et al. have shown that memory T cells 
(CD4+CD44hiCD62Llo) expressing choline acetyltransferase (ChAT) stimulate activation of 
eNOS and increase levels of nitrates and nitrites in endothelial cells. Also, T cell ChAT deficient 
mice have elevated arterial blood pressure. These data suggest a potential therapeutic strategy for 
hypertension, through manipulation of T cell mediated vasorelaxation [80]. 
In summary, the data discussed above implicate the innate and adaptive immune responses as 
critical to the development of hypertension. Each individual cell type or product discussed could 
potentially be used as a target of future therapeutics for hypertension, which would be aimed at 
decreasing the inflammatory response in humans in order to complement the various drugs 
already shown to decrease blood pressure. Moving forward, it is necessary to continue to 
investigate these processes and to aspire to fully understand the immune contributions to 
hypertension, a disease that is continually looking more and more autoimmune in nature.  
Goals of Thesis 
Although our understanding of the role of the adaptive immune system in hypertension is 
continuously evolving, signaling pathways inside the T cell enabling their activity during 
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hypertension and also the direct effects their cytokines have on end-organs during disease 
progression remain poorly understood. Moreover, no studies have yet investigated the role of 
salt, a substance of which numerous epidemiological studies have linked to hypertension and of 
which has been demonstrated to cause pathogenic production of IL-17A, a key cytokine in 
hypertension, when given in excess to differentiating Th17 cells in vitro, on its effects on the 
functionality of immune cells in hypertension [81, 82].  
This dissertation aims to address several outstanding questions surrounding the effect of the pro-
inflammatory cytokine IL-17A, produced by Th17 cells, on the kidneys themselves, as well as 
the effect of salt on T cells in hypertension. The salt sensing kinase SGK1, serves as the 
investigative link between the two studies. SGK1 has not only been described as the intracellular 
mediator of the Th17 cell’s pathogenic production of IL-17A in vitro, but is also a canonically 
important mediator of hypertension within kidney cells, where it functions to facilitate salt and 
water reabsorption through modulation of distal tubule sodium transporters, thus, promoting the 
disease. In Chapter 3 we test the hypothesis that SGK1 mediates IL-17A induced salt and water 
retention during hypertension and in Chapter 4 we test the hypothesis that T cell SGK1 is an 
important mediator of hypertension. The findings from the studies performed in this thesis 
enhance our understanding of the role Th17 cells and its cytokines play in hypertension, and also 
identify therapeutic targets that could be used in conjunction with traditional therapies to help 
mitigate the disease. 
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CHAPTER 2 
Materials and Methods 
Mice 
All animal procedures were approved by Vanderbilt University Institutional Animal Care and 
Use Committee (IACUC), and mice were housed and cared for in accordance with the Guide for 
the Care and Use of Laboratory Animals.   
Mice used in Chapter 3: Wild-Type (C57Bl/6J) mice were purchased from Jackson Laboratories, 
Bar Harbor, ME, USA. IL-17A-/- and IL-17F-/- mice were obtained as a generous gift from Dr. 
Yoichiro Iwakura (Tokyo University of Science, Tokyo, Japan) and were generated as previously 
described [83, 84]. Male mice approximately 10-12 weeks of age were used.  
Mice used in Chapter 4: Wild-Type (C57Bl/6J) mice and tgCD4cre mice were purchased from 
Jackson Laboratories, Bar Harbor, ME, USA. SGK1fl/fl mice were obtained as a generous gift 
from Dr. Aniko Naray-Fejes-Toth (Dartmouth College, Hanover, NH, USA) and were generated 
as previously described [85]. Male mice approximately 10-12 weeks of age were used.  
Surgical Procedures and Blood Pressure Measurements  
Angiotensin II infusion: Mice were anesthetized with ketamine/xylazine (90-120 mg/kg + 
10mg/kg) (1:1 volume ratio) and 2 or 4 week osmotic mini-pumps (Alzet, DURECT 
Corporation, model 2002 or 2004)  containing angiotensin II (490 ng/kg/min, Sigma) or vehicle 
(0.08 M sodium chloride/1% acetic acid solution) were inserted subcutaneously.  
DOCA-salt Treatment: Mice were anesthetized with ketamine/xylazine (90-120 mg/kg + 
10mg/kg; 1:1 volume ratio). The left kidney was surgically removed, a DOCA pellet (100mg, 
Innovative Research of America) was inserted subcutaneously, and the drinking water was 
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supplemented with 1% NaCl for 21 days. Control (Sham) mice underwent a similar surgical 
incision but without nephrectomy and received a placebo pellet. Sham mice received regular 
drinking water with no NaCl supplementation. 
Tail Cuff Blood Pressure Measurements: These experiments measure blood pressure non-
invasively. Before the experiment, the person measuring the blood pressure is blinded to the 
animal’s genotype and treatment. 4 animals at a time were placed on an MC4000 Blood Pressure 
Analysis System (Hatteras Instruments) which was pre-warmed to allow for vasodilation through 
footpads. The mice were covered with a magnetic black cover to keep them in place. Tails of the 
mice were threaded through a small blood pressure cuff and gently taped down. The machine 
measures blood pressure in cycles of 10 and generates an average systolic blood pressure. The 
first two rounds of 10 are eliminated from analysis, giving the mice time to acclimate, rounds 3 
and 4 are averaged together to generate a final systolic blood pressure value for the day. The 
animals’ blood pressure is measured two days per week and averaged to produce a final weekly 
value [33].  
Carotid Radiotelemetry Blood Pressure Measurements: These experiments invasively measure 
blood pressure. Mice were anesthetized with ketamine/xylazine (90-120 mg/kg + 10mg/kg; 1:1 
volume ratio). The left common carotid artery was isolated and the catheter connected to the 
transducer was inserted into the carotid and advanced until the tip was just inside the thoracic 
aorta. The transmitter was positioned under the skin on the right flank close to the hindlimb [86]. 
Following telemetry implantation, mice were allowed to recover for 10 days prior to 
implantation of osmotic minipumps (described above). Measurements of blood pressure were 
obtained daily for 4 weeks. 
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Sacrifice of mice: At the end of each experiment, mice were sacrificed using CO2 inhalation. 
Mice were perfused with saline until all blood was cleared from the circulation and then kidneys, 
aortae, and spleen were extracted for preservation or further analysis.  
Transporter profiling (Chapter 3) 
Immunoblotting for NHE3, NCC-total, phosphorylated NCC, and gamma ENaC were performed 
as previously described (Performed by Alicia McDonough’s Laboratory at the University of 
Southern California) [71, 87, 88] 
Urine analysis 
Chapter 3: Mice were placed in metabolic cages for 24 hour urine collection. Albumin was 
measured in the urine using an ELISA kit (Albuwell, Exocell). Immunoblotting for albumin and 
angiotensinogen was performed on urine samples as previously described and according to 
manufacturer’s instructions [87, 88]. 
Chapter 4: Albumin and creatinine concentrations were measured from a spot urine sample [89]  
(obtained after 4 weeks of angiotensin II infusion) using ELISA kits from Exocell. Albumin 
concentration was divided by creatinine concentration in each sample to determine the 
albumin:creatinine ratio. 
Immortalized Cell culture (Chapter 3) 
Cytokines IL-17A, IL-17F, and TNFα were obtained from R&D systems. The SGK1 inhibitor, 
GSK 650394, was obtained from TOCRIS Bioscience. Mouse distal convoluted tubule 
(mDCT15) cells were cultured as previously described [90]. NEDD4-2 deficient mDCT15 cells 
were generated as previously described [91]. HK-2 cells were purchased from ATCC. HK-2 cells 
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or mDCT15 cells were plated in 6 well dishes at a density of 100,000 cells per well and allowed 
to grow to confluency over the ensuing days before experiments were performed. HK-2 cells 
were cultured in Keratinocyte SFM (Invitrogen) media in which the Epidermal Growth Factor 
and Bovine Pituitary Extract were added. Additionally 1% Penicillin/Streptomycin was added to 
the media. mDCT15 cells were grown in DMEM/F-12 50/50 media in which 5% Fetal Bovine 
Serum and 1% Penicillin/Streptomycin were added. mDCT15 cells were serum starved overnight 
before experiments were performed. Cells were treated with experiment specific doses of IL-
17A, IL-17F, TNFα and/or GSK 650394. 
Immunoblotting (Chapter 3) 
For p78SGK1 or NHE3: HK-2 cells or mDCT15 cells plated in 6 well dishes were scraped in 
cold sorbitol buffer (5% sorbitol, 5mM histidine/imidazole, 0.5mM EDTA with protease and 
phosphates inhibitors) to isolate protein. Protein was quantified using a Bradford Assay Kit. 
Samples (30µg of protein) were separated by SDS-PAGE. Samples were then transferred to a 
nitrocelluse membrane and blocked with either 5% BSA or 5% milk. Membranes were probed 
using either NHE3 (Millipore) or p78SGK1 (Cell Signaling Technologies). Membranes were 
then labelled using a BioRad HRP Conjugate and detected with BioRad ECL 
Chemiluminescence solution. Membranes were imaged with a BioRad ChemiDoc Imager. Blots 
were then stripped for 15 minutes and re-probed using an antibody to GAPDH (Santa Cruz 
Biotech). Densitometry was performed using BioRad Image Lab software, and bands of interest 
were normalized to GAPDH. 
For Nedd4-2: Proteins were transferred electrophoretically to PVDF membranes. After blocking 
with 3% BSA, the membranes were probed with corresponding primary antibodies (anti Nedd4-2 
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antibody (Abcam, Cambridge, UK, 1:500), anti-actin (Sigma, 1:1000)) and incubated overnight. 
The blots were washed in TBST. Signal detection for Nedd4-2 and actin was done using 
IRDye800 rabbit anti-goat IgG antibody, (Rockland immunochemicals, dilution 1:10000) and 
subsequent scanning of the membrane by the Odyssey Infrared Imager. Intensity of the protein 
bands was analyzed by using Odyssey Infrared Imaging Software (Li-Cor Biosciences). 
Quantitative RT-PCR 
Chapter 3: Whole kidneys were homogenized in Trizol using a Bead Beater, and lysates were 
then subjected to phenol-chloroform extraction. RNA was isolated using an RNeasy Mini Kit 
(Qiagen). HK-2 cells or mDCT15 cells plated on a 6 well dish were washed and then lysed in 
RLT Buffer and RNA was extracted using an RNeasy Mini Kit (Qiagen). RNA quantity and 
purity was measured using a spectrophotometer. cDNA was made using a High Capacity cDNA 
reverse transcriptase kit (Applied Biosystems). Samples were evaluated for mouse or human 
SGK1 (Taqman), mouse or human IL-17A (SABiosciences), mouse or human GAPDH 
(Taqman), and a primer designed against 18s (SIGMA) that works in both species due to 
sequence conservation. Samples were normalized to GAPDH and then normalized again to one 
of the control samples. The Relative Quantification (RQ) values are plotted. 
Chapter 4: RNA was isolated from T cells using an RNeasy mini kit (Qiagen) according to the 
manufacturer’s instructions. Total RNA was then quantified using a DS-11 Spectrophotometer 
(DeNovix). cDNA was made using a High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems) according to the manufacturer’s instructions. Taqman assay system and probes 
(Thermo Fisher) were used to detect SGK1, NKCC1, alpha ENaC, beta ENaC, gamma ENaC, 
NCC, NCX1, NCX2, NHE1, NHE6, and SCN5A. A Taqman assay system and probe for 
GAPDH (Thermofisher Scientific) was used as an endogenous control.  IL-17A mRNA was 
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quantified using the SYBR Green assay system (RT2 Primer Assay, Qiagen). Primers designed 
against 18s (SIGMA) were used as endogenous control for the SYBR Green assay. Gene 
expression values were calculated based on the comparative Ct method normalized to GAPDH 
or 18s mRNA and displayed as either relative quantification (with one of the control samples set 
to ‘1’) for some experiments or fold induction with every control sample set to ‘1’ for other 
experiments. 
NCC activity assay and lentiviral transduction (Chapter 3) 
mDCT15 cells were incubated at 37°C with vehicle, 100ng/mL IL-17A, 100ng/mL IL-17F, 
100nM GSK 650394, or a combination of the agents. Thirty minutes before uptake, 0.1 mM 
metolazone (an inhibitor of NCC) or vehicle (DMSO) was added to the media. The media was 
then changed to a 22Na+ containing medium with or without 0.1mM metolazone and incubated 
for 20 minutes. Cells were lysed and radioactivity was measured by liquid scintillation. Protein 
concentrations were determined by a BCA assay. Uptakes were normalized to nmol/mg protein. 
NCC activity was defined as the thiazide-sensitive uptake which is the difference in Na uptake 
with or without metolazone [92]. Inhibition of Nedd4-2 in the mDCT15 cells was performed 
using lentiviral transduction as described in Arroyo et al [91]. (Experiments were performed by 
Dr. Benjamin Ko’s laboratory at the University of Chicago). 
Flow cytometry of renal and aortic leukocytes (Chapter 4) 
Single cell suspensions of one kidney were prepared by placing the kidney in digestion media 
containing RPMI 1640, 5% FBS, 2mg/mL Collagenase D (Roche), and 0.1mg/mL DNase I 
(SIGMA). Kidneys were homogenized using AutoMACs Dissociator (Miltenyi Biotech) and 
incubated, shaking, at 37ºC for 20 minutes. Single cell suspensions of thoracic aorta with 
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surrounding perivascular fat were prepared by placing the thoracic aorta in digestion media 
containing RPMI 1640, 5% FBS, 1mg/mL Collagenase A (Roche), 1mg/mL Collagenase B 
(Roche), and 0.1mg/mL DNase I (SIGMA). Aortae were homogenized by hand in 6 well plates 
using curved scissors and incubated, shaking, at 37ºC for 40 minutes (4). Tissue homogenates 
were filtered through a 40µM cell strainer after digestion. Single cell suspensions were stained 
for flow cytometry using the following antibodies/stain: Pacific LIVE/DEAD Fixable Violet 
Dead Cell Stain (Life Technologies), brilliant violet-510-conjugated (BV510) anti-CD45 
antibody (BioLegend, clone 30-F11), peridinin chlorophyll protein-cyanin-5.5-conjugated 
(PerCP-Cy5.5) anti-CD3 antibody (BioLegend, clone 17A2), phycoerythrin-cyanin-7-conjugated 
(PE-Cy7) anti-CD8 antibody (BioLegend, clone 53-6.7), allophycocyanin-Hilite-7-conjugated 
(APC-H7) anti-CD4 antibody (BD Biosciences, clone GK1.5), and Alexa Fluor 488-conjugated 
anti-F4/80 antibody (BioLegend, clone BM8). A known quantity of calibration (counting) beads 
(123count eBeads, eBioscience) was added to each sample prior to analysis. Samples were run 
on a BD FACSCanto II system and analyzed using BD FACSDiva software (BD Biosciences). 
Gates were set using fluorescence minus one (FMO) controls. Results were normalized using the 
bead count and expressed as number of cells per kidney or per thoracic aorta.  
Intracellular staining for cytokine producing lymphocytes from spleen (Chapter 4) 
Spleens were ground and filtered through a 40µM cell strainer and then subjected to red blood 
cell (RBC) lysis using RBC lysis buffer (eBioscience). Approximately 3 x 106 cells were 
resuspended in RPMI medium containing 5% FBS and subsequently stimulated with 4 µL of 
Cell Activation Cocktail containing PMA, ionomycin, and the Golgi inhibitor brefeldin A 
(BioLegend) at 37°C for 3 hours. Cells were then washed and stained first with LIVE/DEAD 
Fixable Violet dead cell stain (Life Technologies). The following surface antibodies were then 
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added to the cells for 30 minutes: PerCP-Cy5.5-conjugated anti-CD3 antibody (BioLegend, 
clone 17A2), BV510-conjugated anti-CD8 antibody (BioLegend, clone 53-6.7) and APC-H7-
conjugated anti-CD4 antibody (BD Biosciences, clone GK1.5). Intracellular staining was then 
performed using the BD Transcription Factor Buffer set according to the manufacturer’s 
instructions (BD Biosciences). Antibodies used for intracellular staining were Alexa-Fluor 488-
conjugated anti-IFN-γ antibody (BD Biosciences, clone XMG1.2) and phycoerythrin (PE)-
conjugated anti-IL17A antibody (Biolegend, clone TC11-18H10.1). Results are expressed as 
percentage of cytokine positive cells relative to total CD4+ or CD8+ cells.  
Measurements of Vascular Reactivity (Chapter 4) 
Isometric tension studies of mesenteric arterioles were performed using 2 mm segments of 
second order mouse mesenteric arterioles dissected free of perivascular fat. Studies were 
performed in a small vessel horizontal wire myograph (Danish Myo Technology, models 610M 
and 620M) containing a physiological salt solution composed of 130 mM NaCl, 4.7 mM KCl, 
1.2 mM MgSO4, 1.2mM KH2PO4, 25mM NaHCO3, 5 mM glucose and 1.6 mM CaCl2. The 
isometric tone was recorded for each vessel using LabChart Pro v7.3.7 (AD Instruments).  The 
vessels were equilibrated over a 20 minute period at 37°C. A passive circumference-tension 
curve was generated for each vessel to determine optimum passive tension to simulate an in vivo 
transmural pressure of 100 mmHg according to the manufacturer's protocol as previously 
described with modifications (37).  After normalization, vessels were contracted with 60 mM 
KCl to assess the integrity of the vessel, and then endothelial-dependent and endothelial-
independent vascular relaxations were tested using increasing concentrations of acetylcholine or 
sodium nitroprusside, respectively, after preconstriction with norepinephrine (10µM). 
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T cell isolation and culture (Chapter 4) 
Spleens were isolated from mice and single cell suspensions were prepared as described above. 
CD4+ and CD8+ naïve T cells, γδ T cells, or CD3+ pan T cells were isolated using Miltenyi cell 
separation kits according to the manufacturer’s instructions and an AutoMACS magnetic cell 
sorter (Miltenyi Biotec). Cells were plated in RPMI 1640 media containing 10% FBS, 1% 
Penicillin/Streptomycin, and 50µM β-mercaptoethanol at a density of 200,000 cells/well in a 96 
well plate that was pre-coated with no azide/low endotoxin anti-CD3 (2 µg/ml) and anti-CD28 (2 
µg/ml) (BD Biosciences). To induce Th17 polarization, cells were treated with 20 ng/mL IL-6, 5 
ng/mL TGF-β1, 10 ng/mL IL-1β, and 10 ng/mL of IL-23 for 72 hours at 37°C. These cytokines 
were purchased from R&D Systems. To determine the effect of sodium chloride (NaCl) on IL-
17A and SGK1 expression, some samples received an additional 40 mM NaCl in addition to the 
Th17 polarizing cytokines described above. For the pharmacological inhibitor studies, cells were 
pretreated for 30 minutes with 100uM hydrochlorothiazide, 5uM spironolactone, 100uM 
furosemide, 100uM bumetanide, or equal volume of the corresponding vehicle (ethanol or 
DMSO). These drugs were purchased from SIGMA. After 30 minutes, cells were treated with 
Th17 polarizing cytokines with or without an extra 40 mM NaCl as indicated. In these studies, 
cells were re-treated with the appropriate inhibitors or vehicle after 48 hours and then harvested 
after an additional 24 hours for a total of 72 hrs incubation at 37°C.  
Statistics  
Data are expressed as mean ± SEM. Telemetry blood pressure data were analyzed between the 
two groups of mice using regression with robust standard errors and consideration of clusters of 
mice. Time was modeled using restricted cubic spline non-linearly in the model. In addition to 
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the time and group identity variable, the interaction between them was included in the model. 
The P-value for the interaction is reported. All other analyses were performed in GraphPad 
Prism using repeated measures ANOVA, two-way ANOVA, one-way ANOVA, ratio paired t-
test, Student’s t-test, and Holm-Sidak’s post-hoc test or Bonferroni correction as specified in the 
figure legends. P values ≤ 0.05 were considered significant. 
 
 35 
CHAPTER 3 
Interleukin 17A regulates renal sodium transporters and renal injury in angiotensin II-
induced hypertension 
Allison E. Norlander1, Mohamed A. Saleh2,3, Nikhil V. Kamat4, Benjamin Ko5, Juan Gnecco6, 
Linjue Zhu2, Bethany Dale1, Yoichiro Iwakura7, Robert S. Hoover8, Alicia A. McDonough4, 
Meena S. Madhur1,2 
 
1Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville TN, 
USA. 2Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University 
Medical Center, Nashville, TN, USA. 3Department of Pharmacology and Toxicology, Faculty of 
Pharmacy, Mansoura University, Mansoura, Egypt. 4Department of Cell and Neurobiology, 
Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 
5Department of Medicine, Chicago University School of Medicine, Chicago, IL, USA. 
6Department of Microbiology, Immunology and Pathology, Vanderbilt University, Nashville, 
TN, USA. 7Research Institute for Biomedical Sciences, Tokyo University of Science, Tokyo, 
Japan, 8Division of Renal Medicine, Department of Medicine, Emory University School of 
Medicine, Atlanta GA, USA 
The contents of this chapter have been published in Hypertension vol. 68 (1), pp. 167-74; July 
2016. 
 36 
Introduction 
Hypertension is a leading cause of cardiovascular disease morbidity and mortality [93]. Yet, the 
pathogenesis of hypertension is still poorly understood, and despite conventional treatment, 
blood pressure remains uncontrolled in nearly half of the hypertensive population [94]. Emerging 
evidence from our group and others implicates innate and adaptive immune cells and the 
cytokines that they produce as pathogenic mediators of this disease and its attendant end-organ 
damage [95, 96].  
Interleukin 17A (IL-17A), a pro-inflammatory cytokine produced predominantly by CD4+ T 
helper 17 (Th17) cells as well as gamma delta T cells, plays an important role in numerous 
autoimmune diseases [97]. We have shown that in response to angiotensin II (Ang II) infusion, 
mice deficient in IL-17A develop an initial increase in blood pressure that is similar to wild type 
(WT) mice but are unable to sustain these elevated pressures. Blood pressure starts to decline 
after 2 weeks and is approximately 30 mmHg lower than Ang II infused WT mice by 4 weeks. 
Moreover, IL-17A-/- mice exhibit reduced vascular inflammation and preserved vascular function 
in response to Ang II infusion compared to WT mice [33].  In keeping with this, Amador et al. 
reported a marked increase in Th17 cells in DOCA-salt treated rats and observed that treating 
DOCA-salt rats with an antibody against IL-17A reduced blood pressure and collagen deposition 
in the heart and kidneys [18]. We recently showed that Ang II treated IL-17A-/- mice have 
preserved diuresis and natriuresis in response to an acute saline challenge unlike Ang II treated 
WT mice which retain salt and water [71]. Consistent with this finding, proximal tubule NHE3 
protein abundance was reduced by 40% in IL-17A-/- mice but not WT mice after 2 weeks of Ang 
II infusion, suggesting a mechanism for enhanced pressure natriuresis in the IL-17A-/- mice.  
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There are 6 isoforms of IL-17: A through F. IL-17A shares 50% sequence similarity with IL-
17F, and both can bind as homo- or heterodimers to the same receptor complex composed of IL-
17RA and IL-17RC subunits [98]. The role of IL-17F in hypertension is previously unknown. 
The goal of the present study was to determine the effect of IL-17A and IL-17F on renal sodium 
transporters after a prolonged (4 week) period of Ang II infusion, a time when the blood pressure 
blunting in IL-17A-/- mice is most prominent. In addition, we investigated whether the effects of 
IL-17A or F are direct effects of these cytokines acting on renal sodium transporters in renal 
epithelial cells. 
Our results demonstrate that IL-17A (but not IL-17F) mediates Ang II induced renal injury and 
regulates renal sodium transporters, namely NHE3 and NCC, through a serum and glucocorticoid 
regulated kinase 1 (SGK1) dependent pathway. Moreover, we found that cultured renal proximal 
tubule and distal convoluted tubule cells produce endogenous IL-17A. This study provides 
mechanistic insight into how inflammatory cytokines can regulate sodium and water balance and 
therefore blood pressure. 
Results 
IL-17A-/- mice fail to sustain the upregulation of distal sodium transporters in response to 
chronic (4 weeks) angiotensin II infusion: Following Ang II infusion, IL-17A-/- mice exhibit an 
initial rise in BP similar to WT mice but are unable to sustain these pressures. BP starts to 
decline around 2 weeks and reaches pressures 30 mmHg lower than Ang II infused WT mice by 
4 weeks (Madhur et al. [95] and Figure 3-1). Therefore, we performed renal transporter profiling 
in whole kidneys of WT and IL-17A-/- mice after 4 weeks of Ang II or vehicle (Sham) infusion.  
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Figure 3-1: Blood pressure is blunted in IL-17A-/-, but not IL-17F-/-, mice following Ang II 
infusion. Tail cuff blood pressures at baseline and during 28 days of Ang II infusion (490 
ng/kg/min) in WT, IL-17A-/-, and IL-17F-/- mice.  Two-way ANOVA followed by the Holm-
Sidak post-hoc test was performed. **P<0.01 vs WT (n=5-13 per group). 
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Interestingly, at this timepoint, there was a marked difference in the activation of distal sodium 
transporters between WT and IL-17A-/- mice. As expected, Ang II increased abundance and 
phosphorylation of NCC and cleavage (activation) of the gamma subunit of ENaC in WT mice, 
but this was abolished in IL-17A-/- mice (Figure 3-2). We previously showed that after 2 weeks 
of Ang II infusion, distal transporters are activated in IL-17A-/- mice but to a lesser degree than 
in WT mice [71]. Taken together, this data shows that IL-17A-/- mice fail to sustain the Ang II 
induced increases in distal convoluted tubule and collecting duct sodium channels, coincident 
with their decline in blood pressure.   
To determine if this effect was specific to the IL-17A isoform, we investigated the effect of IL-
17F on blood pressure and renal sodium transporters using IL-17F deficient mice. Blood pressure 
in IL-17F-/- mice during chronic Ang II infusion was not blunted (Figure 3-1) and distal sodium 
transporter abundance was similar to that observed in WT mice with the exception of a reduction 
in cleaved γENaC (Figure 3-2). Thus, the reductions in blood pressure and distal renal sodium 
transporter abundance are specific to the IL-17A isoform. 
IL-17A regulates renal SGK1 expression: Serum and glucocorticoid regulated kinase 1 (SGK1) 
is an important mediator of salt and water retention in the kidney through inhibition of Nedd4-2 
mediated ubiquitination and degradation of NCC and ENaC in the distal convoluted tubule, 
thereby enhancing the expression of these transporters on the cell surface [99, 100]. We 
hypothesized that SGK1 mediates the effects of IL-17A on renal sodium transporters. To test this 
hypothesis, we performed quantitative RT-PCR on whole kidney lysates from WT and IL-17A-/- 
mice infused with 2 or 4 weeks of Ang II or vehicle (Sham). SGK1 expression was upregulated 
2-fold in kidneys from WT mice infused for 2 or 4 weeks with Ang II (Figure 3-3).  
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Figure 3-2: IL-17A deficiency blunts the Ang II induced increase in distal sodium 
transporters. Abundance of total and phosphorylated Na-Cl cotransporter (t-NCC and p-NCC) 
as well as full length (FL) and cleaved (CL) gamma ENaC were analyzed in whole renal tissue 
homogenates from wild-type (WT), IL-17A-/-, and IL-17F-/- mice after 4 weeks of vehicle (Sham) 
or angiotensin II (Ang II) infusion. Fold change in transporter abundance in Ang II infused mice 
compared to vehicle (Sham) infused mice is shown below. Values are plotted as mean±SEM. 
Student’s t-Test was used to compare transporter abundance in Ang II infused animals to the 
corresponding vehicle infused animals for each genotype. *P≤0.05 (n=5-6 per group). 
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Figure 3-3: IL-17A regulates renal SGK1 expression. WT and IL-17A-/- mice were infused 
with vehicle (Sham) or Ang II for two or four weeks as indicated. Quantitative real time PCR 
was performed on RNA extracted from whole renal tissue homogenates and normalized to 
GAPDH. Relative quantification values are plotted as mean±SEM. Two-way ANOVA followed 
by Bonferroni post-hoc test was used. *P<0.05 (n=5-10 per group). 
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In contrast, kidneys from IL-17A-/- mice had no increase in SGK1 expression after either 2 or 4 
weeks of Ang II infusion (Figure 3-3). This suggests that SGK1 is a potential mediator of the 
effects of IL-17A in the kidney. 
IL-17A, but not IL-17F, directly upregulates NCC activity in cultured mouse distal convoluted 
tubule (mDCT15) cells via an SGK1/Nedd4-2 dependent pathway: To determine if the effect of 
IL-17A on distal tubule sodium transporters was a direct and specific effect, we measured NCC 
activity in a cultured mouse distal convoluted tubule cell line (mDCT15) that has been 
previously characterized and shown to recapitulate many features of in vivo distal convoluted 
tubule cells [90]. NCC activity was defined as the metalozone inhibited increase in radioactive 
sodium uptake. IL-17A, but not IL-17F, significantly increased NCC activity in these cells 
(Figure 3-4A).   
We did not detect an increase in SGK1 mRNA with IL-17A treatment of mDCT15 cells (data not 
shown), but phosphorylation of SGK1 at Serine 78 was increased 1.5 fold after 15 minutes of IL-
17A treatment (Figure 3-4B). Importantly, the IL-17A induced increased in NCC activity was 
abrogated by co-treatment with the SGK1 inhibitor, GSK 650394 (Figure 3-4C). To test the 
hypothesis that the effect of IL-17A and SGK1 on NCC activity is mediated via Nedd4-2, we 
used mDCT15 cells in which Nedd4-2 was silenced by lentiviral transduction of a short hairpin 
RNA (shRNA) targeting Nedd4-2 or a non-targeting shRNA as control. As shown in Figure 3-5, 
the Nedd4-2 shRNA transducted cells expressed approximately 60% less Nedd4-2 protein by 
immunoblotting. In these cells, the basal level of NCC activity was increased, and there was 
virtually no additional effect of IL-17A on NCC activity (Figure 3-4D). Taken together, these 
results suggest that IL-17A induces an increase in NCC activity through phosphorylation of 
SGK1 and inhibition of Nedd4-2 mediated ubiquitination and degradation of NCC.  
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Figure 3-4: IL-17A increases NCC activity in cultured mouse distal convoluted tubule 
(mDCT15) cells via an SGK1/Nedd4-2 dependent pathway. A) NCC activity in mDCT15 
cells with or without treatment with 100ng/mL of IL-17A or IL-17F (n=6 per group). B) 
Representative immunoblot for phosphorylated SGK1 on serine 78 in mDCT15 cells with or 
without 15 min of treatment with recombinant IL-17A (100ng/ml). Quantification of all blots 
relative to GAPDH and normalized to untreated is shown on the right (n=5 per group). C) NCC 
activity in mDCT15 cells after treatment with IL-17A or IL-17A plus 100nM of the SGK1 
inhibitor, GSK 650394 (n=6 per group). D) NCC activity with or without IL-17A treatment in 
mDCT15 cells lentivirally transducted with a short hairpin RNA (shRNA) to silence NEDD4-2 
or a non-targeting shRNA (n=4 per group). All data are plotted as mean±SEM. One-way 
ANOVA followed by Newman-Keuls post-hoc test was used for panels A, C, and D, and a 
paired Student’s t-Test was used for panel B. **P<0.01, ***P<0.001, ****P<0.0001. 
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Figure 3-5. NEDD4-2 shRNA decreases NEDD4-2 expression in mDCT15 cells: 
Representative immunoblot showing amount of NEDD4-2 protein in mDCT15 control cells (C), 
mDCT15 cells transducted with a non-targeting shRNA (NT), and mDCT15 cells transducted 
with an shRNA targeting NEDD4-2 (N4). Actin was used as a loading control. Quantification of 
all blots relative to actin and normalized to control is shown on the right. Repeated measures 
one-way ANOVA followed by the Newman-Keuls post-hoc test was used. ***P<0.001 (n=4). 
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IL-17A upregulates NHE3 in cultured human proximal tubule (HK-2) cells via an SGK1 
dependent pathway: Downregulation of NHE3 is an important mechanism for pressure 
natriuresis. Our previous study [71] demonstrated that IL-17A-/- mice exhibit suppressed NHE3 
abundance at an earlier timepoint (2 weeks) after Ang II infusion compared to WT mice. In the 
current study, we found that IL-17A-/- mice maintained this decrease in NHE3 abundance, and 
that WT mice exhibited a similar decrease in NHE3 abundance by 4 weeks of Ang II infusion 
(Figure 3-6). Thus, while pressure natriuresis eventually occurs in both WT and IL-17A-/- mice, 
it is accelerated in the absence of IL-17A. Thus, we hypothesized that IL-17A has a direct effect 
on NHE3 regulation in proximal tubule cells. To test this hypothesis, we quantified NHE3 
abundance by immunoblotting in cultured human proximal tubule (HK-2) cells treated with or 
without recombinant IL-17A for 72 hours. Using this in vitro system, we were able to remove the 
confounding effects of blood pressure and angiotensin II. Interestingly, IL-17A directly 
upregulated NHE3 protein expression by greater than 2-fold in these cultured cells (Figure 3-
7A).  
To determine whether IL-17A regulates SGK1 in the proximal tubule, we treated HK-2 cells 
with increasing doses of recombinant IL-17A, IL-17F, or tumor necrosis factor alpha (TNFα) for 
24 hours. Interestingly, only IL-17A caused a dose-dependent increase in SGK1 expression by 
quantitative RT-PCR (Figure 3-7B).  We then investigated whether IL-17A treatment also 
increased phosphorylation of SGK1. We found that phosphorylation of SGK1 at Serine-78 
increased 2-fold in HK-2 cells after 15 minutes of treatment with IL-17A (Figure 3-7C). To 
determine whether the IL-17A dependent increase in NHE3 was dependent on SGK1, we treated 
HK-2 cells with increasing doses of the SGK1 inhibitor, GSK 650394, starting 30 minutes prior 
to IL-17A treatment.  
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Figure 3-6: NHE3 expression is blunted in WT and IL-17A-/- mice after 4 weeks of Ang II 
infusion. Abundance of NHE3 in WT and IL-17A-/- mice after 4 weeks of vehicle (Sham) or 
Ang II infusion was analyzed by immunoblotting in whole renal tissue homogenates. 
Quantification data are reported under the blots as mean±SEM. Student’s t-Test was used to 
compare transporter abundance in Ang II infused animals to the corresponding vehicle infused 
animals for each genotype. *P<0.05 (n=5-6 per group). 
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Figure 3-7: IL-17A upregulates NHE3 in cultured human proximal tubule (HK-2) cells via 
an SGK1 dependent pathway. A) HK-2 cells were incubated with or without 100 ng/mL of 
recombinant IL-17A for 72 hours. Representative immunoblot for NHE3 and GAPDH is shown 
with quantification of all blots relative to GAPDH and normalized to untreated shown below 
(n=7 per group). B) HK-2 cells were treated with IL-17A or IL-17F (increasing doses from 1 
ng/ml to 100 ng/ml) or TNFα (1ng/ml or 10ng/mL) for 24 hours. Quantitative real time PCR for 
SGK1 was performed on the cell lysates. Relative quantification normalized to GAPDH is shown 
(n=4 per group). C) Representative immunoblot for phosphorylated SGK1 on serine 78 in HK-2 
cells with or without 15 min of treatment with recombinant IL-17A (100ng/ml). Quantification 
of all blots relative to GAPDH and normalized to untreated is shown below (n=4 per group). D) 
HK-2 cells were pretreated for 30 min with vehicle or the SGK1 inhibitor, GSK 650394, at the 
indicated concentrations and subsequently treated with or without 100ng/mL of IL-17A for 72 
hours. A representative immunoblot for NHE3 and GAPDH is shown. Quantification of all blots 
relative to GAPDH and normalized to untreated is shown below (n=3 per group). All data are 
plotted as mean±SEM. One-way ANOVA followed by Bonferroni post-hoc test was used for 
panels B and D, and a paired Student’s t-Test was used for panels A and C.  *P<0.05, **P<0.01, 
***P<0.001. 
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The SGK1 inhibitor reduced the basal expression of NHE3 and caused a dose-dependent 
decrease in the IL-17A induced NHE3 expression (Figure 3-7D) indicating that the effect of IL-
17A on NHE3 in proximal tubule cells is mediated by SGK1. Taken together, these data 
demonstrate that IL-17A increases expression and phosphorylation of SGK1 in the proximal 
tubule leading to increased abundance of NHE3. 
IL-17A-/- mice are protected from glomerular and tubular injury in response to angiotensin II 
infusion: Albuminuria is a marker of glomerular injury and is known to increase in response to 
Ang II induced hypertension. To determine the effect of IL-17A and IL-17F on glomerular 
injury, we measured urinary albumin by ELISA on 24-hr urine samples from WT, IL-17A-/-, and 
IL-17F-/- mice after 4 weeks of vehicle (Sham) or Ang II infusion. WT and IL-17F-/- mice 
exhibited a marked increase in albuminuria while IL-17A-/- mice were completely protected from 
glomerular injury during Ang II infusion (Figure 3-8A). We then performed immunoblotting to 
confirm this finding and to quantify urinary angiotensinogen (a marker of tubular injury) in these 
24 hr urine samples from WT and IL-17A-/- mice. Interestingly, Ang II infusion induced a 
marked increase in urinary angiotensinogen in WT mice and this was absent in IL-17A-/- mice 
(Figure 3-8B). Thus IL-17A, but not IL-17F, contributes to the renal end-organ damage that 
occurs as a result of Ang II induced hypertension.  
Renal proximal and distal convoluted tubule cells produce endogenous IL-17A: We showed that 
IL-17A plays an important role in the regulation of renal sodium transporters both in vivo and in 
vitro. However, a key question is what is the source of IL-17A in the kidney? We and others 
have observed an accumulation of immune cells, particularly T lymphocytes, in the kidneys of 
animals and humans with hypertension [95, 96]. However, there is also evidence that renal 
epithelial cells may produce their own cytokines such as IL-6, IL-8, and TNF-α [101-103].  
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Figure 3-8: IL-17A-/- mice are protected from glomerular and tubular injury in response to 
angiotensin II infusion. WT, IL-17A-/-, or IL-17F-/- mice were infused with vehicle (Sham) or 
Ang II for 4 weeks and then placed in metabolic cages for 24 hours for urine collection. A) 
Albuminuria was measured via ELISA and corrected for urine volume. B) Urinary albumin and 
angiotensinogen were measured by immunoblot and relative abundance for each group is plotted 
below. Data are expressed as mean±SEM. Two-way ANOVA followed by Newman-Keuls post-
hoc test was used in panel A. Student’s t-Test was used in panel B to compare protein levels in 
Ang II infused animals to the corresponding vehicle infused animals for each genotype. *P<0.05, 
**P<0.01, ****P<0.0001 (n=5-6 per group). 
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By RT-PCR, we confirmed the previously reported observation [104] that HK-2 cells produce 
IL-17A. Interestingly, we also found that mDCT15 cells express IL-17A (Figure 3-9). This was 
not observed in mouse pulmonary artery smooth muscle cells or human aortic endothelial cells. 
RNA from mouse CD4+ T cells polarized towards the Th17 lineage served as a positive control. 
Thus, IL-17A produced by renal tubular cells themselves or from infiltrated T cells can regulate 
sodium absorption, renal injury, and blood pressure.  
Discussion 
A major cause and complication of hypertension is renal dysfunction leading to increased 
sodium and water retention which promotes a rise in blood pressure and compensatory pressure 
natriuresis. Here we show that the pro-inflammatory cytokine, IL-17A, produced by immune 
cells as well as renal epithelial cells, can induce the expression and activity of both proximal and 
distal sodium transporters through an SGK1 dependent pathway, thus counteracting pressure 
natriuresis and contributing to sodium retention (Figure 3-10). Moreover, loss of IL-17A 
protects against glomerular and tubular injury in response to Ang II induced hypertension as 
evidenced by attenuation of albuminuria and urinary angiotensinogen levels in the IL-17A-/- 
mice.  In contrast, deficiency of the related cytokine, IL-17F, has little or no effect on blood 
pressure and renal transporter expression. Interestingly, the effect of IL-17A on renal transporters 
is dependent on the duration of Ang II infusion. We previously reported that after 2 weeks of 
Ang II infusion, IL-17A-/- mice down-regulated NHE3, while NHE3 expression was unchanged 
in WT mice. In both groups, distal sodium transporters such as NCC and ENaC were activated 
(although to a lesser extent in the IL-17A-/- mice) [71]. Blood pressure starts to normalize in the 
IL-17A-/- mice after 2 weeks of Ang II infusion, reaching pressures 30 mmHg lower than Ang II 
infused WT mice by 4 weeks (Madhur et al.[95] and Figure 3-1).  
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Figure 3-9: IL-17A is produced endogenously by both the mDCT15 and HK-2 kidney cell 
lines: Representative RT-PCR gel for IL-17A in mDCT15 and HK-2 cells. Mouse Th17 
polarized CD4 T cells were used a positive control. IL-17A mRNA was not detected in 2 other 
cell lines, mouse pulmonary artery smooth muscle cells (SMCs) and human aortic endothelial 
cells. 18s was used as a control for RNA integrity.  
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Figure 3-10: Schematic illustrating the effects of IL-17A (endogenous and T cell derived) 
on both proximal and distal tubule cells in the kidney. 
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At this 4 week timepoint, the major differences between WT and IL-17A-/- mice are seen in the 
distal tubule. IL-17A-/- (but not WT) mice have significant blunting of the activation of distal 
sodium transporters. These are key transporters in the regulation of blood pressure as evidenced 
by the fact that thiazide diuretics, pharmacological inhibitors of NCC, are still one of the most 
effective drugs in the treatment of hypertension [105].  
Moreover, many of the Mendelian forms of hypertension are due to mutations that influence the 
activity of NCC and/or the amiloride-sensitive ENaC. Thus, the blood pressure reduction 
observed after 4 weeks of Ang II infusion in IL-17A-/- mice is likely due to decreased activity of 
distal sodium transporters. In fact, our data suggests that IL-17A inhibition may be as or more 
effective than the use of thiazide diuretics or amiloride in the treatment of hypertension and the 
resultant glomerular and tubular injury.   
Urinary angiotensinogen is a biomarker of tubular injury as well as an indicator of the intrarenal 
renin-angiotensin system (RAS) activity. It is interesting to note that Ang II infusion failed to 
induce an increase in urinary angiotensinogen in the IL-17A-/- mice. In response to Ang II, 
proximal tubule cells produce greater levels of angiotensinogen which leads to increased Ang I 
release into the tubule lumen and subsequently conversion to Ang II by local angiotensin 
converting enzyme. Ang II then acts on the distal tubule and collecting duct to increase 
expression of NCC and ENaC [106]. Satou et al. showed that prolonged treatment of renal 
proximal tubule cells with interferon-γ results in increased angiotensinogen production in these 
cells. Interferon-γ may thus indirectly activate distal sodium transporters via stimulation of the 
intrarenal RAS system [107]. It is conceivable that IL-17A may be functioning in a similar 
manner. However, we did not see an elevation of angiotensinogen by qRT-PCR after IL-17A 
treatment of HK-2 cells (data not shown). Moreover, our in vitro studies show that IL-17A can 
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stimulate NCC activity in cultured cells. Nevertheless, we cannot rule out a potential effect of 
IL-17A on the intrarenal RAS in vivo. 
Of note are the differential effects seen between IL-17A versus IL-17F. Although they share 
50% sequence similarity and bind the same receptor complex, our results indicate that IL-17A 
(but not IL-17F) regulates NCC activity, renal injury, and hypertension [97].  
Limitations of the present study include the use of one specific mouse strain and one model of 
hypertension, namely angiotensin II infusion. In addition, we have only tested the effects of IL-
17 isoforms on one proximal tubule and one distal tubule cell line. Thus, additional studies using 
other animal strains, cell lines, and different models of hypertension are necessary to generalize 
these findings.  
Monoclonal antibodies to IL-17A or the IL-17RA receptor have recently been developed for 
human use. In 2015, the FDA approved the first IL-17A antagonist Secukinumab (a human 
monoclonal antibody that selectively binds to IL-17A) for the treatment of moderate to severe 
plaque psoriasis. Also in development are drugs such as Brodalumab, a monoclonal antibody that 
targets the IL-17RA receptor subunit. This drug is awaiting FDA approval for the treatment of 
moderate to severe psoriasis. Our data suggests that targeting IL-17A or the IL-17RA/RC 
receptor complex may be a novel therapeutic strategy for the treatment of hypertension and the 
associated renal dysfunction.  
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Introduction 
Hypertension is a leading cause of death and disability from cardiovascular and renal diseases 
including myocardial infarction, heart failure, stroke, and chronic kidney disease. The rising 
prevalence of hypertension, due in part to changes in diet and food processing, makes it a major 
global health concern. In the U.S. alone, hypertension afflicts approximately one-third of all 
adults over 18 years of age, and this rises to two-thirds by the age of 60 [108]. In 2010, high 
blood pressure was ranked as the leading single risk factor for global burden of disease [2].  
Evidence from our group and others has demonstrated that hypertension is an inflammatory 
disease characterized by T cell activation, infiltration of target organs such as the kidney and 
vasculature, and production of cytokines that lead to salt and water retention, vascular 
dysfunction, and renal injury [17, 71, 109, 110]. Most notably, we previously demonstrated that 
mice deficient in the pro-inflammatory cytokine interleukin 17A (IL-17A) exhibit blunted 
hypertension, attenuated vascular inflammation, and preservation of vascular function in 
response to angiotensin II induced hypertension [33]. Recently, we showed that IL-17A regulates 
proximal and distal renal sodium transporters and contributes to angiotensin II induced renal 
injury (Chapter 3) [110]. IL-17A is produced by a subset of CD4+ T helper cells (Th17 cells), a 
subset of CD8+ cytotoxic T cells (Tc17 cells), and a distinct subset of innate-like gamma delta T 
cells (γδT17 cells). We found that Th17 cells and γδT17 cells are the major sources of IL-17A in 
the kidney and vasculature following angiotensin II induced hypertension [111]. 
Of note, numerous epidemiological and experimental studies have demonstrated a link between 
dietary salt intake and hypertension [112]. Interestingly, there is now emerging evidence that salt 
can directly influence immune cell function. Two recent studies demonstrated that elevated 
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extracellular sodium chloride concentrations of 190 mM, presumably similar to levels found in 
the interstitium of animals fed a high-salt diet [113, 114], promoted the polarization of naïve T 
cells into Th17 cells through a serum and glucocorticoid regulated kinase 1 (SGK1) dependent 
pathway [81, 82]. Using a mouse model of multiple sclerosis known as experimental 
autoimmune encephalomyelitis (EAE), Wu et al. [81] showed that high salt feeding resulted in 
increased numbers of Th17 cells in the central nervous system and mesenteric lymph nodes and 
led to a more rapid and severe form of EAE, an IL-17A mediated disease, in control animals. 
Interestingly, mice with T cell deficiency of SGK1 exhibited a significantly reduced EAE 
incidence and severity that was not further exacerbated by high salt feeding. Thus, in addition to 
regulating salt-responsiveness of T cells, SGK1 appears to mediate salt-independent T cell, and 
particularly Th17 cell, pathogenicity in autoimmune disease. 
Given the importance of IL-17A in hypertension, we therefore hypothesized that T cell SGK1 
plays a key role in salt dependent and independent hypertension and hypertensive end-organ 
damage. To test this hypothesis, we generated mice with T cell specific deletion of SGK1 and 
induced hypertension using angiotensin II infusion or uninephrectomy followed by 
deoxycorticosterone acetate – salt (DOCA-salt) treatment. We found that loss of SGK1 in T cells 
blunts hypertension and completely abrogates renal/vascular inflammation and protects against 
hypertensive renal and vascular injury. Furthermore, we detected the expression of multiple 
sodium channels and sodium transporters on T lymphocytes and provide evidence that the 
sodium-potassium-2 chloride cotransporter 1 (NKCC1) is upregulated in Th17 cells and 
mediates the salt-induced increase in SGK1. Taken together, these results demonstrate that T cell 
SGK1 and NKCC1 may serve as novel therapeutic targets for the treatment of hypertension.  
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Results 
T cell SGK1 deficiency attenuates angiotensin II-induced hypertension  
To determine the role of T cell SGK1 in hypertension, we generated mice with T cell specific 
deletion of SGK1 by crossing SGK1fl/fl mice with transgenic mice expressing cre recombinase 
under the control of the CD4 promoter (tgCD4cre). T cells that express CD4 at any stage during 
development should undergo cre-recombination and deletion of SGK1. We first investigated the 
role of T cell SGK1 in angiotensin II (Ang II) induced hypertension. We verified knockdown of 
SGK1 in CD4+ and CD8+ T cells, SGK1 is knocked down in both cell types because they go 
through a double positive stage during development in the thymus, and demonstrate that SGK1 is 
knocked down in some γδ T cells in our T cell culture model (Figure 4-1A-C) [115]. Blood 
pressure (BP) in SGK1fl/fltgCD4cre mice and SGK1fl/fl controls was measured both noninvasively 
using the tail-cuff method and invasively using carotid radiotelemetry in freely moving mice. 
BPs in vehicle-infused (Sham) mice were similar between SGK1fl/fltgCD4cre mice and SGK1fl/fl 
controls, demonstrating that T cell deletion of SGK1 does not affect baseline BP (Figure 4-2A). 
However, following infusion of a pressor dose of Ang II (490/ng/kg/min) for 28 days, systolic 
BP was 25 mmHg lower in the SGK1fl/fltgCD4cre mice compared to the SGK1fl/fl controls as 
measured by both tail cuff and telemetry (Figure 4-2A-B). Diastolic BPs and mean arterial BPs 
were similarly reduced in the SGK1fl/fltgCD4cre mice compared to controls while heart rates were 
similar between both groups (Figure 4-2C-E). As a secondary control, to confirm that cre 
recombinase expression in T cells is not responsible for the blunted hypertensive phenotype, we 
measured BP in tgCD4cre mice at baseline and weekly (2 days per week) using carotid 
radiotelemetry during 28 days of Ang II infusion.   
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Figure 4-1. SGK1 expression is 
abolished in CD4+ and CD8+ T 
cells and some γδ T cells in 
SGK1fl/fltgCD4cre mice. Naïve CD4+ T cells (A), naive CD8+ T cells (B), 
or γδ T cells (C) were isolated from spleens of SGK1fl/fl control and SGK1fl/fltgCD4cre mice and cultured for 3 days on anti-CD3/anti-CD28 coated plates in the presence of Th17 polarizing cytokines plus an excess 40mM NaCl to maximize SGK1 expression which was then quantified by qRT-PCR (*P<0.05, **P<0.01; Student’s t-test; n = 4-6 per group). All data are expressed as mean ± SEM. 
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Figure 4-2. T cell SGK1 deficiency attenuates angiotensin II (Ang II)-induced hypertension. 
(A) Systolic blood pressures measured noninvasively using the tail-cuff method over 28 days of 
Ang II (490ng/kg/min) or vehicle (Sham) infusion in SGK1fl/fl and SGK1fl/fltgCD4cre mice 
(**P<0.01 between both Ang II infused groups; repeated measures ANOVA/Holm-Sidak’s post 
hoc test; n = 6-7 per group). (B) Systolic blood pressures, (C) Mean arterial pressures, (D) 
Diastolic blood pressures, and (E) Heart rates measured using invasively using carotid 
radiotelemetry over 28 days of Ang II infusion in SGK1fl/fl and SGK1fl/fltgCD4cre mice (*P<0.05, 
***P<0.001; regression analysis; n = 6-7 per group). All data are expressed as mean ± SEM.  
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The systolic, diastolic and mean arterial pressures of the tgCD4cre mice increased similarly as the SGK1fl/fl controls (Figure 4-3A-C). Heart rate was similar among all 3 groups of mice (Figure 4-2E and Figure 4-3D). 
T cell SGK1 deficiency prevents Ang II induced vascular and renal inflammation 
We and others have shown that Ang II increases total leukocyte and T cell infiltration into the 
perivascular fat and kidneys, and that this is likely an important causal factor for the progression 
of hypertension and the development of end-organ damage [17, 38, 72].  
To determine the role of T cell SGK1 on vascular and renal inflammation, we performed flow 
cytometry on single cell suspensions of the thoracic aorta and kidney following 28 days of Ang 
II infusion in SGK1fl/fltgCD4cre mice and SGK1fl/fl controls. Representative flow cytometry dot 
plots and gating strategy to detect total leukocytes (CD45+ cells), total T lymphocytes 
(CD45+CD3+ cells), and T cell subsets (CD4+, CD8+ and double negative (DN) cells) in the 
thoracic aorta are shown in Figure 4-4A. Baseline levels of total leukocytes and T cells were 
similar in both groups as shown after vehicle infusion (Sham) in SGK1fl/fl controls and 
SGK1fl/fltgCD4cre mice (Figure 4-4B-F). Ang II infusion markedly increased total leukocytes, 
total T cells, and T cell subsets in SGK1fl/fl control mice while this response was completely 
absent in the SGK1fl/fltgCD4cre mice (Figure 4-4B-F). Representative flow cytometry dot plots 
and gating strategy to detect renal inflammation are shown in Figure 4-5A. Quantification of 
renal total leukocytes and T cells were similar in both groups after vehicle infusion (Sham) 
(Figure 4-5B-F).  
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Figure 4-3. Cre recombinase expression in T cells does not affect Ang II-induced blood 
pressure response. Telemetry recordings of (A) systolic blood pressures, (B) mean arterial 
pressures, (C) diastolic blood pressures, and (D) heart rates in tgCD4cre mice infused with Ang II 
(490ng/kg/min) for 28 days. Data were recorded for 2 days at baseline and weekly thereafter 
during Ang II infusion. All data are expressed as mean ± SEM (n = 5). 
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Figure 4-4. T cell SGK1 deficiency prevents Ang II-induced vascular inflammation. (A) 
Representative flow cytometry dot plots showing gating strategy for total leukocytes (CD45+ 
cells), total T lymphocytes (CD45+CD3+ cells), and T cell subsets (CD4+, CD8+, and CD3+CD4-
CD8- double negative (DN) cells) in single cell suspensions from the thoracic aorta of SGK1fl/fl 
and SGK1fl/fltgCD4cre mice infused with Ang II or vehicle (Sham) for 28 days. (B-F) Summary 
data of absolute numbers of indicated cell types per thoracic aorta (*P<0.05, **P<0.01; two-way 
ANOVA/Holm-Sidak’s post hoc test; n = 5-10 per group). All data are expressed as mean ± 
SEM. 
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Figure 4-5. T cell SGK1 deficiency prevents Ang II-induced renal inflammation. (A) 
Representative flow cytometry dot plots showing gating strategy for total leukocytes (CD45+ 
cells), total T lymphocytes (CD45+CD3+ cells), and T cell subsets (CD4+, CD8+, and CD3+CD4-
CD8- double negative (DN) cells) in single cell suspensions from one kidney of SGK1fl/fl and 
SGK1fl/fltgCD4cre mice infused with Ang II or vehicle (Sham) for 28 days. (B-F) Summary data of 
absolute numbers of indicated cell types per kidney (*P<0.05 **P<0.01; two-way 
ANOVA/Holm-Sidak’s post hoc test; n = 6-9 per group). All data are expressed as mean ± SEM.  
 65 
As seen in the aorta, Ang II infusion increased renal total leukocytes and T cell subsets only in 
SGK1fl/fl controls while SGK1fl/fltgCD4cre mice were completely protected from Ang II induced 
renal inflammation. Taken together, these results suggest that T cell SGK1 is required for the 
development of hypertensive renal and vascular inflammation. 
T cell SGK1 deficiency protects against Ang II induced vascular and renal injury 
Hypertension is characterized by endothelial dysfunction and glomerular injury [17, 33]. We 
assessed vascular function of resistance vessels by measuring endothelium-dependent and –
independent relaxation of second order mesenteric arterioles from SGK1fl/fl controls and 
SGK1fl/fltgCD4cre mice. Mesenteric arterioles from SGK1fl/fl control mice exposed to 4 weeks of 
Ang II infusion displayed impaired relaxation to acetylcholine compared to vessels isolated from 
vehicle (Sham) infused mice (Figure 4-6A). 
 Importantly, mesenteric arterioles from SGK1fl/fltgCD4cre mice displayed no impairment in 
endothelium-dependent relaxation following Ang II infusion (Figure 4-6B). Endothelium-
independent relaxation to sodium nitroprusside was not affected by Ang II infusion in both 
groups of mice (Figure 4-6C-D).  
We then examined renal injury in these mice by measuring the albumin:creatinine ratio in spot 
urine following 4 weeks of vehicle (Sham) or Ang II infusion. Albuminuria is a well-known 
marker of glomerular injury and has been shown to increase following Ang II infusion in WT 
mice [17, 110]. For these experiments, we used tgCD4cre mice as a secondary control. Ang II 
infusion resulted in a marked increase in albuminuria in both control groups, SGK1fl/fl and 
tgCD4cre mice, while the increase in albuminuria in SGK1fl/fltgCD4cre mice was blunted and non-
significant (Figure 4-6E).  
 66 
Figure 4-6. T cell SGK1 deficiency protects against Ang II-induced vascular and renal 
injury. SGK1fl/fl controls, tgCD4cre controls, and SGK1fl/fltgCD4cre mice were infused with Ang II 
or vehicle (Sham) for 28 days. Endothelium-dependent relaxation to increasing doses of 
acetylcholine (Ach) was measured in (A) SGK1fl/fl mice and (B) SGK1fl/fltgCD4cre mice, and 
endothelium-independent relaxation to increasing doses of sodium nitroprusside (SNP) was 
measured in (C) SGK1fl/fl mice and (D) SGK1fl/fltgCD4cre mice (**P<0.05; repeated measures 
ANOVA/Holm-Sidak’s post-hoc test; n=4-6 per group). (E) Urinary albumin to creatinine ratio 
in the indicated groups (*P<0.05, **P<0.01, ***P<0.001; one-way ANOVA/Holm-Sidak’s post-
hoc test; n = 8-14 per group). All data are expressed as mean ± SEM. 
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Thus, the absence of renal and vascular inflammation following Ang II infusion in T cell SGK1 
deficient mice correlates with protection from Ang II induced renal and vascular injury.  
T cell SGK1 deficiency abrogates Ang II induced increase in splenic Th17 cells  
We previously showed that Ang II infusion was associated with an increase in IL-17A 
production from circulating and splenic CD4+ T cells [17, 33]. To determine the effect of SGK1 
on Th17 cell numbers in vivo in response to Ang II infusion, we performed intracellular staining 
and flow cytometry on splenic single cell suspensions from vehicle (Sham) and Ang II infused 
SGK1fl/fl controls and SGK1fl/fltgCD4cre mice. Representative flow cytometry images of IL-17A 
producing CD4+ T cells (Th17 cells) and CD8+ T cells (Tc17 cells) are shown in Figure 4-7A. 
Ang II infusion resulted in a 2-fold increase in splenic Th17 cells in SGK1fl/fl control mice, and 
this was completely abrogated in SGK1fl/fltgCD4cre mice (Figure 4-7B).  
Splenic Tc17 cells were not affected by Ang II infusion or loss of T cell SGK1 (Figure 4-7C). 
Interferon gamma (IFNγ) is produced by CD4+ Th1 and CD8+ Tc1 cells and has been shown to 
play an important role in hypertension [17]. By intracellular staining and flow cytometry, we did 
not detect any differences in splenic Th1 or Tc1 percentages in response to Ang II infusion or 
loss of T cell SGK1 (Figure 4-8A-C).  
T cell SGK1 deficiency attenuates hypertension and vascular inflammation in a DOCA-salt 
model of hypertension  
Since SGK1 has been shown to mediate salt induced Th17 polarization and maintenance [81, 
82], we investigated the role of T cell SGK1 in a deoxycorticosterone acetate (DOCA)-salt 
model of hypertension in which uninephrectomy is accompanied by implantation of a DOCA 
pellet and supplementation of the drinking water with 1% NaCl.  
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Figure 4-7. T cell SGK1 deficiency abrogates Ang II-induced increase in splenic Th17 cells. 
(A) Representative flow cytometry dot plots for CD4+IL-17A+ Th17 cells and CD8+IL-17A+ 
Tc17 cells in splenic single cell suspensions from SGK1fl/fl and SGK1fl/fltgCD4cre mice infused 
with Ang II or vehicle (Sham) for 28 days. (B-C) Summary data of percentages of CD4+IL-17A+ 
Th17 cells out of total CD4+ cells and CD8+IL-17A+ Tc17 out of total CD8+ cells in the indicated 
groups (*P<0.05; one-way ANOVA/Holm-Sidak’s post-hoc test; n=8-12 per group). All data are 
expressed as mean ± SEM.  
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Figure 4-8. Frequency of splenic Th1/Tc1 cells is not altered by Ang II infusion or loss of T 
cell SGK1. (A) Representative flow cytometry dot plots for CD4+IFNγ+ Th1 cells and 
CD8+IFNγ+ Tc1 cells in splenic single cell suspensions from SGK1fl/fl and SGK1fl/fltgCD4cre mice 
infused with Ang II or vehicle (Sham) for 28 days. (B-C) Summary data of percentages of 
CD4+IFNγ+ Th1 cells out of total CD4+ cells and CD8+IFNγ+ Tc1 cells out of total CD8+ cells in 
the indicated groups. All data are expressed as mean ± SEM (n=9-12 per group).  
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The development of hypertension was blunted in the SGK1fl/fltgCD4cre mice with systolic BPs 
reaching 15 mmHg lower than SGK1fl/fl controls at days 14 and 21 of DOCA-salt treatment 
(Figure 4-9A). DOCA-salt treatment was associated with an increase in total CD45+ leukocytes 
and CD3+ T cells in the thoracic aorta in SGK1fl/fl control mice, and this was abrogated in 
SGK1fl/fltgCD4cre mice (Figure 4-9B-F). Thus, T cell SGK1 appears to play an important role in 
both salt-dependent and –independent hypertension. 
NKCC1 is upregulated in Th17 cells and mediates the salt-induced increase in SGK1  
To understand how T cells sense extracellular NaCl, we first isolated and cultured naïve CD4+ or 
CD8+ splenic T cells under Th17 polarizing conditions with or without an excess 40 mM NaCl 
for 3 days. Expression of IL-17A and SGK1 was measured in these cells by qRT-PCR.  
As previously shown in CD4+ T cells [81, 82], we found that IL-17A and SGK1 are upregulated 
in both CD4+ and CD8+ T cells upon exposure to Th17 polarizing cytokines and further 
increased by high salt treatment (Figure 4-10A-D). We then isolated pan T cells from spleens of 
WT mice and performed RT-PCR for a panel of sodium channels and transporters. We were able 
to detect expression of all the channels and transporters listed in Table 4-1. Of note, NKCC2, a 
renal specific isoform of NKCC, was not detected in T cells.  
To determine which of these channels/transporters might mediate the salt effect on T cells, we 
tested various pharmacological inhibitors of sodium transporters as well as an antagonist of the 
mineralocorticoid receptor (which has been previously shown to regulate the Th17 response to 
DOCA-salt treatment in rats [18]).  
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Figure 4-9. T cell SGK1 deficiency attenuates hypertension and vascular inflammation in a 
DOCA-salt model of hypertension. (A) Systolic blood pressures measured noninvasively using 
the tail-cuff method in SGK1fl/fl and SGK1fl/fltgCD4cre mice in response to DOCA-salt treatment 
over 21 days (*P<0.05; repeated measures ANOVA/Holm-Sidak’s post hoc test; n = 8-10 per 
group). (B-F) Summary flow cytometry data of absolute numbers of total leukocytes (CD45+ 
cells), total T lymphocytes (CD45+CD3+ cells), and T cell subsets (CD4+, CD8+, and CD3+CD4-
CD8- double negative (DN) cells) per thoracic aorta in SGK1fl/fl and SGK1fl/fltgCD4cre mice after 
21 days of DOCA-salt or vehicle (Sham) treatment (*P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001, two-way ANOVA/Holm-Sidak’s post hoc test; n = 8-15 per group). All data are 
expressed as mean ± SEM. 
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Figure 4-10. Salt enhances SGK1 and IL-17A expression in CD4+ and CD8+ T cells exposed 
to Th17 polarizing cytokines. Naïve splenic CD4+ T cells (A and C) and CD8+ T cells (B and 
D) were isolated from C57Bl/6J wild type (WT) mice and cultured for 72 hours on anti-
CD3/anti-CD28 coated plates in the presence or absence of Th17 polarizing cytokines (IL-1β, 
IL-6, IL-23, TGF-β) (Cytokines) with or without an excess 40 mM NaCl (Salt) as indicated. IL-
17A expression (A and B) and SGK1 expression (C and D) were quantified by qRT-PCR and 
expressed as fold change relative to untreated cells (*P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001; ratio-paired t-test between the indicated groups; n = 5-9 per group). All data are 
expressed as mean ± SEM.  
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Table 4-1. Sodium channels and transporters expressed by T cells. Pan CD3+ T cells were 
isolated from spleens of C57Bl/6J wild type mice and RT-PCR was performed for the indicated 
sodium channels/transporters. Expression was not changed with infusion of Ang II.  
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Naïve CD4+ T cells were cultured as above with Th17 polarizing cytokines or Th17 polarizing 
cytokines plus salt along with hydrochlorothiazide (inhibits NCC), spironolactone (inhibits the 
mineralocorticoid receptor), furosemide (inhibits NKCC1), or bumetanide (inhibits NKCC1). 
SGK1 expression was measured by qRT-PCR.  
Interestingly, treatment with either furosemide or bumetanide abrogated the salt induced increase 
in T cell SGK1 expression, suggesting that NKCC1 plays a critical role in the ability of T cells to 
sense salt, while the other agents had no effect (Figure 4-11A). We then quantified NKCC1 
expression by qRT-PCR in naïve CD4+ T cells that were untreated or treated with Th17 
polarizing cytokines ± salt. NKCC1 was significantly upregulated in CD4+ T cells cultured under 
Th17 polarizing conditions with a modest further increase when salt was added to the culture 
media (Figure 4-11B). Taken together, NKCC1 appears to be induced in Th17 cells and mediate 
the salt induced increase in T cell SGK1 expression. 
Discussion 
Hypertension is a major health concern worldwide, and its prevalence has been compounded by 
the high salt content of modern processed foods. Among patients with hypertension who report 
taking prescribed medications, only two-thirds have their blood pressure under control [108]. 
Moreover, even in patients with reasonable blood pressure control, hypertension is associated 
with an elevated risk of cardiovascular events [116, 117] presumably due to an unaddressed 
inflammatory process. But how does salt and inflammation converge to cause hypertension and 
end-organ damage? Here we show that the salt-sensing kinase, SGK1, in T lymphocytes is 
critical to the development of hypertension in response to two different hypertensive stimuli – 
angiotensin II infusion and DOCA-salt treatment.  
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Figure 4-11. NKCC1 is upregulated in Th17 cells and mediates the salt-induced increase in 
SGK1. (A) Naïve splenic CD4+ T cells were isolated from C57Bl/6J wild type (WT) mice and 
cultured for 72 hours on anti-CD3/anti-CD28 coated plates in the presence or absence of Th17 
polarizing cytokines (Cytokines), an excess 40 mM NaCl (Salt), and co-treatment with DMSO or 
ethanol (vehicle) or hydrochlorothiazide, spironolactone, furosemide or bumetanide as indicated. 
SGK1 expression was quantified by qRT-PCR and expressed as fold change relative to untreated 
cells (*P<0.05, **P<0.01, ****P<0.0001; ratio-paired t-test between the indicated groups with 
Bonferroni correction for the drug treatment groups; n = 19 in the first three groups and n = 5-7 
in each drug treatment group). (B) Naïve splenic CD4+ T cells from WT mice were cultured as 
described above and sodium-potassium-2 chloride co-transporter 1 (NKCC1) expression was 
quantified by qRT-PCR and expressed as fold change relative to untreated cells (*P<0.05, 
***P<0.001; ratio-paired t-test between the indicated groups; n = 9 per group). Bars represent 
mean ± SEM. 
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Furthermore, we show that NKCC1 is upregulated in Th17 cells and mediates the T cell response 
to salt. While loss of T cell SGK1 resulted in a significant reduction in the blood pressure 
response to both stimuli, it should be noted that blood pressure was still elevated above normal in 
both models. However, despite this persistent mild elevation in blood pressure, it is remarkable 
that vascular and renal inflammation and vascular and renal injury were virtually completely 
abolished by the loss of SGK1 in T cells. This highlights the need to possibly redefine treatment 
goals in hypertension to focus on reducing the inflammatory substrate that leads to end-organ 
damage rather than just focusing on the blood pressure itself.  
SGK1 is well known for its role in modulating sodium transport in renal epithelial cells of the 
distal convoluted tubule through upregulation of ENaC and NCC [118]. Recently, Wu et. al and 
Kleinewietfeld et. al described a novel role for SGK1 in the stability and maintenance of Th17 
cells by phosphorylation and inactivation of FoxO1, a direct repressor of the interleukin 23 (IL-
23) receptor. IL-23 signaling in Th17 cells maintains the Th17 cell phenotype [81, 82]. 
Hernandez et al. and Safa et al. subsequently showed that SGK1 inhibits T regulatory (Treg) 
cells at least in part by phosphorylating and inhibiting both FoxO1 and FoxO3, which are 
important in regulating Foxp3 expression. Foxp3 is the signature transcription factor required for 
Treg function [119, 120]. Treg cells have been shown to suppress Ang II induced hypertension 
and vascular injury [77]. Thus, the mechanism by which loss of T cell SGK1 protects against 
hypertension and end-organ damage is likely through a shift in the Th17/Treg balance. Indeed, 
we observed a reduction in percentage of Th17 cells in the spleen following Ang II infusion in 
our T cell SGK1 deficient mice compared to SGK1fl/fl controls (Figure 4-7B). 
Salt has also recently been shown to influence antigen-presenting cells such as macrophages. Salt 
boosts the activation of classical, lipopolysaccharide-induced M1 macrophages and blunts the 
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activation of alternative M2 macrophages [121, 122]. Zhang et al. described a specific activation 
state of macrophages induced by high salt which they termed M (Na). This state is characterized 
by enhanced expression of pro-inflammatory genes and suppressed expression of anti-
inflammatory genes [123]. Kirabo et al. demonstrated that dendritic cells activate T cells in 
hypertension through presentation of isoketal-modified peptides [34]. Of note, the cytokines 
released by these activated dendritic cells are Th17 polarizing cytokines (IL-6, IL-1β, and IL-23). 
Thus, in addition to a direct effect of salt on T cells, salt induced activation of T cells in vivo 
could be potentiated through enhanced activation of antigen presenting cells. Nevertheless, our 
results demonstrate that deleting SGK1 in T cells alone is sufficient to protect against 
hypertension and more importantly, against the renal and vascular damage that accompanies 
hypertension.   
An important result of our study is that loss of T cell SGK1 was protective in a salt-independent 
Ang II model of hypertension. There are at least two possible explanations for this. First, Ang II 
would be predicted to increase aldosterone, which would then lead to sodium and water retention 
in the kidney. Indeed, we have shown that animals retain sodium and water after Ang II infusion 
[59]. Recent work by Titze and colleagues has challenged conventional paradigms of salt 
homeostasis by demonstrating that animals and humans can store sodium in their skin, muscle, 
and lymphatics at concentrations exceeding that of plasma without a commensurate increase in 
water [124]. Thus, Ang II infusion may be associated with increased tissue levels of sodium. 
Alternatively, Ang II may directly or indirectly increase T cell SGK1 expression or function. We 
did not detect an increase in T cell SGK1 expression when we added Ang II to our T cell culture 
media (data not shown). However, this does not exclude an effect of Ang II on T cell SGK1 
expression or function in vivo. Of note, Ang II has been shown to increase SGK1 expression and 
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phosphorylation in other cell types [125, 126]. Moreover, other signals associated with 
hypertension such as endothelin, glucocorticoids, oxidative stress, and certain cytokines have 
been shown to increase SGK1 transcription in various contexts [127]. Thus, T cell SGK1 may be 
a final common pathway by which multiple stimuli cause T cell activation in hypertension. 
Interestingly, T cell SGK1 deficiency was associated with a dramatic absence of T cell 
infiltration into the kidney and vasculature in response to hypertension. One potential possibility 
for this is that SGK1 affects chemokine receptors on T cells. However, we performed qRT-PCR 
screening for a number of different chemokine receptors on T cells from SGK1fl/fl controls and 
SGK1fl/fltgCD4cre mice following Ang II infusion and did not detect any difference in chemokine 
receptor expression (data not shown). We and others have shown that IL-17A can induce 
chemokine expression in mouse mesangial cells and human aortic smooth muscle cells [33, 128]. 
These chemokines are involved in the recruitment of T cells and monocytes. Thus, through an 
overall reduction in IL-17A production, loss of T cell SGK1 may be associated with reduced 
chemokine expression and thus attenuated inflammatory cell recruitment into these tissues. 
Another intriguing possibility is that SGK1 is involved in T cell migration. Using furosemide 
and bumetanide, we showed that ion transport through NKCC1 mediates SGK1 upregulation in 
high salt conditions. Kochl et al recently demonstrated that With No Lysine 1 (WNK1) kinase 
regulates T cell migration through an NKCC1 dependent pathway [129]. The authors showed 
that NKCC1 deficiency or treatment with bumetanide reduced CCL21 induced migration of 
CD4+ T cells. Further studies are needed to determine whether NKCC1 mediated T cell 
migration may involve signaling through SGK1. 
The finding that furosemide and bumetanide inhibit salt-induced T cell SGK1 expression 
suggests that these commonly used diuretics may actually have a previously unrecognized anti-
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inflammatory effect. It is interesting to speculate that these drugs not only help to excrete 
sodium, but that they may also block the effect of dietary salt on T cells, shifting the balance 
from a Th17 to a Treg phenotype. Future studies are needed to determine the role of T cell 
NKCC1 in blood pressure regulation and whether blocking NKCC1 specifically in T 
lymphocytes would have a beneficial effect on hypertension and hypertensive end-organ 
damage. 
One limitation of this study is that we deleted SGK1 primarily in CD4+ and CD8+ T cells and 
only a subset of γδ T cells. We previously showed that γδ T cells are a major source of IL-17A 
in the kidney and vasculature in Ang II induced hypertension [111]. The role of SGK1 and/or 
salt on γδT cell function is unknown. Nevertheless, we did see a major effect on hypertension 
and renal/vascular inflammation in our model, suggesting that loss of SGK1 in primarily CD4+ 
and CD8+ T cells is sufficient to confer protection from hypertensive stimuli. Another limitation 
is that it is unclear how the excess salt concentrations that we and others have used in vitro 
correlates with tissue sodium concentrations in vivo in hypertensive animals and humans. It is 
difficult to quantify tissue sodium in animals, although one study by Wiig et al using energy 
dispersive X-ray spectrometry/scanning electron microscopy (EDX-SEM) demonstrated that 
sodium concentrations in the lymph capillaries of DOCA-salt treated rats reached levels 
comparable to what we used in cell culture [114]. In humans, 23Na magnetic resonance imaging 
has demonstrated an increase in skin and muscle sodium with aging and hypertension, but due to 
the methodology used to quantify tissue sodium, a direct correlation with cell culture sodium 
concentrations is not possible [114].  
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In conclusion, we have demonstrated that the salt-sensing kinase SGK1 in T lymphocytes plays a 
critical role in regulating blood pressure and more importantly, renal and vascular inflammation 
and injury in experimental models of hypertension. Moreover, NKCC1 in T cells may play an 
important role in how T cells sense and respond to elevated sodium chloride in the extracellular 
environment. Future studies into how much and where we store sodium and how other signals in 
addition to sodium activate T cell SGK1 will lead to a deeper understanding of the interplay 
between salt, inflammation, and hypertension and lead to novel therapeutic targets for this 
widespread disease. 
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CHAPTER 5 
Conclusions and Future Directions 
Synopsis 
Hypertension has become a worldwide health concern, and is an important contributor to 
cardiovascular morbidity and mortality [4, 130]. Specifically, renal and vascular dysfunction, 
which are both causes and consequences of hypertension, can lead to the development of 
complications that include myocardial infarction and chronic kidney disease, among others 
[131]. Throughout the past decade, researchers have intensely focused on uncovering the role 
inflammation and the immune system play in the development and maintenance of hypertension. 
Our laboratory and others have determined that both T cells and dendritic cells are important 
mediators of hypertension, as animals develop a blunted hypertensive response when deficient in 
either of these cell types [29, 34, 38]. Our laboratory previously demonstrated that deficiency of 
IL-17A, produced by CD4+ Th17 cells as well as gamma delta (γδ) T cells, results in blunted 
hypertension and preserved vascular function [33]. However, little was known regarding the 
actions of IL-17A in the kidney. Epidemiological studies have also associated excess dietary salt 
intake with the development of hypertension but the precise mechanism by which salt promotes 
hypertension was poorly understood. Interestingly, recent studies have linked excess salt to 
pathogenic IL-17A production by Th17 cells [81, 82] via a serum and glucocorticoid-regulated 
kinase 1 (SGK1) dependent pathway. Moreover, SGK1, a salt-sensing kinase, has also been 
shown to regulate salt and water retention in the kidney through increased surface expression of 
distal sodium transporters such as the sodium chloride co-transporter (NCC) and the epithelial 
sodium channel (ENaC) [81, 82, 132].  Furthermore, a recent study evaluated polymorphisms 
located in SGK1 in a cohort of hypertensive humans who had completed a dietary salt protocol. 
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Rao et al. found that two different single nucleotide polymorphisms (SNPs) in SGK1 were 
associated with elevated blood pressure in humans on a high salt diet; suggesting genotypic 
analysis of SGK1 in humans could identify individuals prone to salt-sensitive hypertension, 
connecting SGK1 to human hypertension [133]. Therefore, the overall goal of this dissertation 
was to determine the role of the SGK1-IL-17A axis in T lymphocytes and the kidney in 
regulating sodium transport and hypertension. I made the following key observations: 
1. IL-17A, produced by Th17 cells and locally by tubule cells, acts through SGK1 on 
proximal tubule cells to enhance sodium/hydrogen exchanger 3 (NHE3) expression and 
acts through SGK1 on distal tubule cells to enhance sodium/chloride cotransporter (NCC) 
activity resulting in enhanced sodium and water retention (Chapter 3). 
2. T cell SGK1 is an important mediator of salt dependent and independent hypertension. 
Deficiency of T cell SGK1 results in blunted blood pressure, abrogated vascular/renal 
inflammation, and preserved vascular/renal function. Sodium/Potassium/2 Chloride 
Cotransporter 1 (NKCC1) mediates the excess salt induced activation of SGK1 in Th17 
cells (Chapter 4). 
Synthesis of Inflammatory Pathways in Hypertension 
As a whole, this thesis adds to the ever increasing body of evidence linking the immune system 
to the development of hypertension by discovering mechanisms through which salt and IL-17A 
act to promote hypertension and by identifying biomarkers in human monocytes (Appendix A) 
that confirm the importance of inflammasome activation in hypertensive human subjects. We 
now believe that inflammation begins as a result of disruption of the Renin-Angiotensin-
Aldosterone System (RAAS). Traditionally, renin, a proteolytic enzyme, is released into 
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circulation by the juxtaglomerular cells of the kidney in response to a decrease in renal perfusion 
pressure. Renin acts on angiotensinogen, a hormone present in circulation, converting it to 
angiotensin I. Subsequently, angiotensin converting enzyme (ACE), present in the lungs and 
kidney, converts angiotensin I to angiotensin II. Angiotensin II has many direct effects that result 
in increased blood pressure; these include increasing sympathetic activity, promoting 
vasoconstriction, promoting tubular salt and water reabsorption, and increasing levels of reactive 
oxygen species (ROS), among others [134, 135]. Importantly, angiotensin II also promotes 
secretion of aldosterone from adrenal glands. Aldosterone directly acts to enhance salt and water 
reabsorption in the kidney. Enhanced activation of this system thus results in hypertension by 
increasing systemic vascular resistance and promoting salt and water reabsorption [136, 137]. 
We hypothesize that excess sodium is stored in tissues such as the skin and skeletal muscle, and 
increased salt leads to the activation of NADPH oxidase in dendritic cells. Dendritic cells (DCs) 
then produce even more ROS. This leads to the formation of isoketals which adduct to lysine 
residues on proteins in the DCs themselves. DCs are then able to present these isoketal-adducted 
proteins to T cells resulting in their activation [34, 51]. Importantly, ROS also activates the 
NLRP3 inflammasome in DCs [138]. Activation of the inflammasome leads to production of the 
cytokines IL-18 and IL-1β. IL-1β, in combination with IL-6 and TGF-β also secreted by DCs, 
promotes differentiation of T cells into IL-17A producing Th17 cells [19, 139, 140]. Th17 cells 
differentiated in areas with elevated interstitial sodium produce increased amounts of IL-17A 
[81, 82, 141]. IL-17A then further promotes vascular dysfunction by causing impaired 
vasodilation, vascular stiffness and increased inflammation [109]. IL-17A also causes renal 
dysfunction and injury by promoting enhanced expression/activity of renal sodium transporters 
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and by inducing glomerular damage (Chapter 3). Thus, IL-17A through induction of vascular 
and renal dysfunction, contributes to worsening of hypertension (Figure 5-1). 
Outstanding Questions/Future Directions 
Why do inflammatory cytokines alter renal transporter expression and/or activity? 
The results described in Chapter 3 contribute to a newer body of evidence demonstrating the 
ability of pro-inflammatory cytokines to alter the abundance and activity of renal sodium 
transporters. We found that IL-17A acts on distal tubule cells to enhance NCC and epithelial 
sodium channel (ENaC) abundance after chronic (4 weeks) angiotensin II infusion. In a previous 
paper, we showed that IL-17A acts on proximal tubule cells to enhance NHE3 expression after 2 
weeks of angiotensin II infusion [71]. We then verified the actions of IL-17A on both distal 
tubule NCC and proximal tubule NHE3 using cultured cell lines. Together, these papers suggest 
that IL-17A biphasically regulates renal sodium channel expression during hypertension, 
impacting proximal tubule channels first and later enhancing expression of distal channels. 
However, IL-17A is not the only pro-inflammatory cytokine able to alter renal sodium channel 
function. In our previous paper, we were also able to demonstrate that IFN-γ regulates the 
abundance of NHE3, NCC and NKCC2 [71]. Additionally, Zhang et al identified a pathway 
through which IL-1β signaling in renal myeloid cells decreases nitric oxide production within the 
kidney resulting in enhanced sodium reabsorption through NKCC2 [32]. Moreover, IL-6 has 
been shown to regulate ENaC in cultured cortical collecting duct cells and also angiotensinogen, 
which is converted to angiotensin II by the intrarenal renin-angiotensin system and can then act 
to regulate local sodium channels, in cultured proximal tubule cells [66, 142]. All of these studies 
beg the same important questions; specifically, how and why are these cytokines altering renal 
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transporter expression and functionality? Our findings have shed some light on the mechanisms 
behind the effects of IL-17A on renal sodium transporter expression. However, further studies 
are needed to identify the precise mechanisms by which IL-17A acts to activate SGK1 in the 
proximal tubule, and also if SGK1’s actions resulting in enhanced NHE3 expression after IL-
17A treatment are mediated by any of the sodium/hydrogen exchanger regulatory cofactor 
(NHERF) scaffolding proteins. Future studies can also investigate the importance of locally 
produced IL-17A by the renal tubule cells themselves on basal control of channel expression. 
Broadly, understanding the mechanisms behind the actions of other cytokines (e.g. IL-1β, IFNγ, 
IL-6) on renal sodium transporter abundance and activity as well as identifying other cytokines 
that could contribute to regulation, such as the anti-inflammatory cytokine IL-10, is essential to 
dissecting the pathophysiology of hypertension and also for the identification of therapeutic 
targets. In regards to why pro-inflammatory cytokines have these functions, it is possible that 
these mechanisms evolved to help the body fight off infections. Studies have demonstrated that 
increased sodium helps to promote pathogenic functions of innate and adaptive immune cells 
[81, 82, 120, 123]. Thus, the immune system may have evolved a way, through pro-
inflammatory cytokine activation of renal transporters, to boost its own functions during times of 
need, in a feed-forward fashion, to help ward off pathogens. However, activation of the immune 
system in response to oxidative stress or autoantigens that results in hypertension and other 
autoimmune diseases may lead to inadvertent and chronic enhanced sodium reabsorption that 
contributes to exacerbation of disease pathology. 
Where do T cells see elevated sodium concentrations and how do they sense it? 
Increased dietary salt intake and also activation of renal sodium transporters by immune cell 
produced cytokines are two methods by which our bodies can, in theory, increase their sodium 
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stores, and importantly, both methods have been linked to hypertension [71, 143]. If worsening 
of hypertension is indeed due to activation and proliferation of cells of the immune system in 
locations where sodium concentrations reach levels of 190mmol/L, the amount determined by 
Wu et al. and Kleineweitfeld et al. that induces the most IL-17A production by Th17 cells, where 
are T cells chronically seeing such high levels of sodium [81, 82]? The answer may lie in recent 
research by Dr. Jens Titze and colleagues whose group has demonstrated that both animals and 
humans can store elevated concentrations of sodium in their skin, muscle and lymphatics. 
Interestingly, storage of sodium in these areas occurred without a commensurate increase in 
water [124]. The prior dogma was that water and sodium must be stored together in such a way 
as to maintain equilibrium between plasma and extracellular tissue sodium concentration. While 
23Na MRI is currently being used in select sites to quantify tissue sodium in humans, it has 
proven more difficult to quantify tissue sodium in animals. One method, however, energy 
dispersive X-ray spectrometry/scanning electron microscopy (EDX-SEM), is promising and was 
performed by Wiig et al in a study involving DOCA-salt treated rats; additionally, Titze and 
colleagues commonly ash mice to determine organ sodium content [114]. Currently, our 
laboratory is attempting to optimize 23Na MRI on anesthetized mice in order to visualize 
locations of elevated sodium content. Understanding where and how much sodium T cells 
encounter during hypertension is important to designing specialized therapeutics to combat the 
inflammatory aspect of this disease. 
In addition to understanding where T cells see excess sodium, it is necessary to understand how 
T cells sense excess sodium when exposed to it. Our findings demonstrate that Th17 cells, in 
particular, sense and respond to excess sodium through the sodium channel NKCC1. These data 
have significant implications as the commonly prescribed diuretics, bumetanide and furosemide, 
 87 
which both inhibit NKCC1 and NKCC2, may be exerting an anti-inflammatory effect. Our data 
also revealed that T cells isolated from spleens of mice express at least 8 different sodium 
channels/subunits or transporters at baseline. Thus, it will be essential in future studies to 
determine which T cell subsets express which channels/transporters; and whether salt, via influx 
through these or other channels, alters T cell function in hypertension. Additionally, it is crucial 
to extrapolate this concept to other immune cell types. For example, do dendritic cells, 
macrophages, monocytes, B cells, etc. express sodium channels? Are they functional? Are we 
also inhibiting the actions of these cell types by administering diuretics to patients? All of these 
questions are important to answer if we want to truly understand the pathogenesis of 
hypertension and how salt and inflammation converge to worsen the disease. 
Significance of IL-17A inhibition as a potential anti-hypertensive treatment: an alternative or 
addition to diuretics? 
In Chapter 3 we put forth evidence demonstrating that global deletion of IL-17A blunts the 
development of albuminuria, a marker of renal injury, in response to 4 weeks of angiotensin II 
infusion in comparison to WT mice. As stated in the synopsis, global deletion of IL-17A was 
also linked previously by our laboratory to preservation of vascular function and blunted blood 
pressure responses to 4 weeks of angiotensin II infusion [33]. Together, these papers suggest that 
treatment of sustained hypertension with monoclonal antibodies to either IL-17A or its receptor, 
IL-17RA, would result in the lowering of blood pressure and preservation of the current state of 
functionality of the kidneys and the vasculature. This hypothesis was supported by data in a 
paper we recently published. We demonstrated that administration of IL-17A or IL-17RA 
monoclonal antibodies to mice during weeks 3 and 4 of a 4 week administration of angiotensin II 
resulted in a reduction of blood pressure and levels of renal/vascular inflammation and renal 
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albuminuria compared to mice administered control IgG monoclonal antibody [68]. Thus, it is 
possible that IL-17A monoclonal antibodies as a treatment for hypertension could replace the use 
of diuretics, as we suggest in our published discussion from Chapter 3, as they combat 
inflammation in addition to preserving renal function. However, this theory was called into 
question due to evidence discovered later which was described in Chapter 4 and discussed in 
relation to salt in the previous section. As stated, furosemide and bumetanide actually act to 
block the excess salt induced pathogenic phenotype of Th17 cells and thereby inhibit an aspect 
of the underlying inflammatory condition in hypertension. Thus, future studies in this area would 
explore the actions of monoclonal antibodies and diuretics in combination to battle established 
hypertension. It is possible that treating mice for the second two weeks of a 4 week angiotensin 
II experiment with both diuretics and anti-IL-17A or anti-IL-17RA monoclonal antibodies would 
result in an additive effect and lower blood pressure even more. Or, they would act in 
conjunction to provide long term and stable preservation of kidney function lowering the risk of 
development of chronic kidney disease. Or, we would discover that one works better than the 
other after directly comparing animals treated with diuretics versus animals treated with anti-IL-
17A or anti-IL-17RA antibodies during the same experiment. Thus, it is important to understand 
how these drugs would work together and if there is benefit for prescribing both or one versus 
the other, as many patients with uncontrolled hypertension take more than 3 different drugs to 
combat their blood pressure and the fewer they need the better. With that said, currently, two 
drugs Secukinumab (which binds IL-17A selectively and is FDA approved) and Brodulamab 
(which selectively binds the IL-17A receptor and is currently recommended for approval by an 
FDA advisory panel) act on the IL-17A pathway and are used to treat psoriasis patients. Future 
studies can employ the treatment of hypertensive patients with these drugs in addition to or in 
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replacement of their current drug regimen to determine if the effects seen in mice extend to 
humans, if they do, that would imply that treatment with anti-IL-17A or anti-IL-17RA 
monoclonal antibodies is a therapeutic option for the general population battling the disease. 
Contribution of SGK1 in other cell types to hypertensive development 
SGK1 is a salt sensing kinase, however, it also responds to numerous other stimuli including 
mineralocorticoids, oxidative stress and cytokines [127]. Oxidative stress, cytokines, and 
aldosterone, a mineralocorticoid, have all been linked to hypertension and stimulate or activate 
multiple types of immune cells. Our model, in which we deleted SGK1 in T cells by crossing 
SGK1 floxed mice with mice expressing cre recombinase under the control of the CD4 
promotor, deleted SGK1 in most CD4+ and CD8+ T cells and a subset of γδ T cells. We found 
that this deletion blunts blood pressure, abrogates renal/vascular inflammation, and preserves 
renal/vascular function. If deleting SGK1 in just one component of immune cells results in such 
a drastic attenuation of disease, it stands to reason that a molecule that is activated by so many 
things could contribute to worsening of disease through its activation in other immune cell types, 
and therefore is worth investigating. First, as stated in Chapter 4 in detail, it is necessary to 
explore deletion of SGK1 in all γδ T cells, as they are such an avid producer of IL-17A during 
hypertension.  Additionally, some dendritic cells express CD4 on their cell surfaces [144, 145]. 
As such, we have effectively deleted SGK1 in a subset of dendritic cells. To date we have not 
classified the importance of this subset of dendritic cells to the development of hypertension in 
our model. Still, we may have impacted the functionality of a subset of dendritic cells, 
potentially impacting their ability to activate the adaptive immune response in this disease. In 
relation, salt boosts the activation of M1 macrophages while suppressing the activation of M2 
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macrophages [121, 122]. Thus, it stands to reason that salt may affect the functionality of 
dendritic cells as well since macrophages and dendritic cells can both differentiate from a 
common progenitor, the monocyte. Moreover, Kirabo et al. described the excess production of 
reactive oxygen species by dendritic cells isolated from mice infused with angiotensin II [34].  
As SGK1 is stimulated by both of these substances, active dendritic cells may need functional 
SGK1 in order to uptake or present antigen, or to migrate appropriately to activate T cells, 
without these cells possessing functional SGK1, the disease may be attenuated. Thus, the 
combination of altering T cell and some dendritic cell function may explain why the reduction in 
inflammation in our model in response to angiotensin II and DOCA-salt was so dramatic. 
Ongoing and future studies will therefore explore the functionality of CD4+ SGK1 deficient 
dendritic cells in hypertension and their responsiveness to salt and oxidative stress. 
Conclusion 
Taken together, the studies described in this thesis have advanced our knowledge of the impact 
Th17 cells, their cytokine IL-17A, and their interaction with salt have on the pathophysiology of 
hypertension (Figure 5-1). It has become clear that the effects of IL-17A on hypertensive end-
organ damage is multi-factorial, and adds further evidence to support the idea that hypertension 
itself is an autoimmune disease. Our findings also helped to decipher why salt, in excess, is 
detrimental to people with hypertension, as it is able to promote the response of pathogenic Th17 
cells. Ultimately, these studies further back the importance of evaluating anti-IL-17A 
monoclonal antibodies as therapy for hypertension and also have identified SGK1 in T cells as a 
novel target for hypertensive therapeutics.  
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Figure 5-1. Thesis Summary Schematic. Salt flows into T cells resulting in upregulation of 
SGK1 and increased production of IL-17A. IL-17A acts on the kidneys and vasculature resulting 
in end-organ damage/dysfunction and hypertension.  
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Introduction 
Hypertension is a leading cause of death from myocardial infarction, stroke, heart failure, and 
chronic kidney disease. Emerging evidence from our group and others indicates that 
hypertension is an inflammatory disease in which antigen presenting cells, particularly 
monocyte-derived dendritic cells, present neo-antigens to T lymphocytes which then leads to T 
cell activation, infiltration of target organs, and the production of pro-inflammatory cytokines 
that cause sodium and water retention, vascular dysfunction, and renal injury [29, 34, 109, 110, 
146].  
Circulating monocytes are pluripotent cells capable of differentiating into dendritic cells, 
macrophages, and microglial cells based on environmental cues. Monocytes can also present 
antigen without changing phenotype. Monocytes from patients with hypertension secrete more 
pro-inflammatory cytokines (including interleukin 1β, IL-1β)[147, 148], demonstrate enhanced 
migration [149], exhibit increased adherence to endothelial cells[150], and produce more 
reactive oxygen species [150]. However, these prior studies used monocytes from patients that 
were either untreated or temporarily stopped treatment. Therefore, an important question is 
whether monocytes from treated hypertensive individuals are still dysfunctional and whether 
correcting this dysfunction would lead to improved blood pressure and cardiovascular risk 
reduction. Interestingly, Kirabo et al. [34] recently demonstrated that monocytes from treated 
hypertensive patients exhibit higher levels of isoketals, which are oxidatively modified fatty 
acids that can adduct to proteins, potentially leading to the formation of neo-antigens.  
To understand more thoroughly the genes and pathways that are altered in hypertensive 
monocytes, we performed RNA sequencing of the entire monocyte transcriptome from 5 
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normotensive and 7 treated hypertensive individuals. We identified genes that were differentially 
expressed between the two groups and validated several of them in an independent cohort of 6 
normotensive and 9 hypertensive subjects. The identified transcriptomic signature of 
hypertensive monocytes suggests enhanced inflammasome activity in hypertension. Importantly, 
the identified transcripts could potentially serve as biomarkers for disease severity and as novel 
therapeutic targets.  
Methods 
Patients: Whole blood (40 ml) was obtained from 5 normotensive and 7 hypertensive subjects 
recruited at Vanderbilt for the original cohort. One normotensive subject was sampled on 2 
separate days to obtain a technical replicate that could be used to test the internal consistency of 
the RNAseq assay. An additional 6 normotensive and 9 hypertensive subjects were recruited for 
the validation cohort. Hypertension was defined as a systolic blood pressure greater than 140 
mmHg, a diastolic blood pressure greater than 90 mmHg, or treatment with antihypertensive 
agents, regardless of blood pressure. Exclusion criteria were confirmed or suspected secondary 
causes of hypertension, diabetes mellitus type I or II, concomitant illness requiring 
corticosteroids or immunosuppressants, recent (within 3 months) vaccination against any 
infectious agent, active ongoing malignancy, severe psychiatric disorders, or the presence of 
HIV/AIDS. Informed consent was obtained prior to the blood draw. The protocol was approved 
by the Vanderbilt Institutional Review Board.  
Monocyte Isolation and RNA extraction: Whole blood was mixed 1:1 with cold PBS + EDTA. 
The mixture was layered on top of Ficoll (GE life sceinces) and centrifuged for 30 minutes. The 
‘buffy coat’ layer was isolated and washed 3 times with cold PBS + EDTA. The isolated 
 95 
peripheral blood mononuclear cells (PBMCs) were stained using Monocyte Isolation kit II, 
human (Miltenyi) and the monocytes were negatively selected using an AutoMACs cell 
separator. Monocytes were spun down and RNA was extracted using an RNeasy kit (Qiagen), 
which included a DNaseI treatment step. The purity and quantity of RNA samples were 
measured using a Denovix DS-11 Spectrophotometer or a NanoDrop ND-1000 
Spectrophotometer. 
RNA Sequencing:  cDNA library construction and RNA sequencing was performed by 
VANTAGE (Vanderbilt Technologies for Advanced Genomics). cDNA Library preparation was 
accomplished using the Illumina TruSeq stranded mRNA Sample Preparation Kit, and Rev. D of 
the protocol. Samples were sequenced on the Illumina HiSeq 2500 using v3 SBS chemistry.  
Libraries were sequenced on a Single Read 50bp run at 30 million passing filter reads/sample. 
Details of RNA Sequencing protocols are available on: 
http://vantage.vanderbilt.edu/resources/grant-text/. 
RNA Sequencing Analysis: A total of 13 samples were obtained from 12 patients (their 
characteristics are in Table A-1). Based on post-alignment quality assurance and control 
(QA/QC), all samples were of high fidelity; i.e., Phred quality score = 37.00 ± 0.31, indicating a 
high probability that the bases were accurately identified. The Phred score = -10*log10 
(Probability of Error). For all 13 samples, the base call accuracy was estimated to be > 99.9%. 
For statistical analyses, samples were separated into two groups: hypertensive (n = 7) and 
normotensive (n = 5). Two samples were collected for one of the 5 normotensive subjects 
(technical replicates), obtained on separate days, allowing us to perform two separate sets of 
analyses to increase the robustness of the data and reduce false positives due to RNASeq 
technical variation.  
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 Normotensive  
Controls (n=5) 
Hypertensive 
Patients (n=7) 
p value 
Age (years) 47.9±6.8 50.4±2.7  
Sex (F/M) 4/1 7/0  
Race (W/B) 5/0 6/1  
Duration of HTN (years) NA 8.9±4.8  
Systolic BP (mmHg) 112.6±7.2 136.7±5.7 <0.02 
Diastolic BP (mmHg) 64.8±4.8 78.5±5.7 <0.06 
MAP (mmHg) 80.7±5.0 97.9±5.0 <0.03 
BMI (kg/m2) 26.9±3.9 33.4±3.7  
Antihypertensive Drugs:    
ACEi  3  
ARB  2  
ACEi + TZ + CCB  1  
CCB  1  
 
Table A-1: Demographics table for original cohort: n = number of subjects in each group, 
HTN = hypertension, BP = blood pressure, MAP = mean arterial pressure, BMI = body mass 
index. ACEi=angiotensin converting enzyme inhibitors; ARB=angiotensin AT1 receptor 
blockers; TZ=thiazide diuretics; CCB=dihydropyridine calcium channel blockers. Significant 
and borderline results for the unpaired t-test and chi-square comparisons between groups are in 
the rightmost column. Lack of a value indicates lack of statistical significance. 
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Analysis 1 included all hypertensive and normotensive subjects (true biological replicates), with 
the normotensive replicated subject represented by the first sample. Analysis 2 was identical to 
Analysis 1, except the second sample from that subject was used. While we were interested in 
obtaining a global view of transcriptional differences between hypertensive and normotensive 
subjects, we especially wanted to identify transcripts with the highest likelihood of being true 
and reproducible findings. For this purpose, we employed 12 separate methodologies (6 each for 
Analysis 1 and 2), using various combinations of alignment, quantification, statistical, and 
annotation strategies. As shown in Table A-2, this strict analysis yielded a total of 60 transcripts 
that were identified as significant (multiple hypothesis-corrected p value < 0.05; fold difference 
> 1.5). 
Quantitative RT-PCR: Monocyte RNA was converted to cDNA using a High Capacity cDNA 
Reverse Transcriptase Kit (Applied Biosystems). The cDNA was then probed for the following 
genes; all probes were purchased from Taqman: Arg1, CCL4, MMP8, VSIG4, PGLYRP1 and 
IL18RAP. Results were normalized to GAPDH and subsequently normalized to 1 of the 
normotensive patients. The data are plotted as Relative Quantification values. 
Statistics: Statistical analysis for RNAseq was performed using Partek Flow, with the following 
parameters: Alignment: STAR and TopHat2/Bowtie2; Quantification: Cufflinks and P/E 
(Partek’s optimization of the expectation-maximization algorithm [151]); Statistics: Cuffdiff, 
GSA, and ANOVA; Annotations: RefSeq and Aceview. Stepwise multivariate regression 
analyses were carried out to identify genes, the expression of which (log10 of normalized RPKM; 
reads per kilobase per million mapped reads) could be a determinant of blood pressure. 
Univariate correlation analysis was used for hypothesis generation.  
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Alignment Quant Stats Annot 
Analysis 
Set 1 
Analysis 
Set 2 
Total 
(1 OR 2) 
Common 
(1 AND 
2)  
Number RNA entities with p<0.05, FD > 
1.5 
STAR Partek E/M 
GSA RefSeq 624 651 810 465 Aceview 1,790 1,670 2,280 1,180 
ANOVA RefSeq 525 549 698 376 Aceview 1,643 1,535 2,104 1,074 
Bowtie2 + 
TopHat2 Cufflinks CuffDiff 
RefSeq 1,155 1,115 1,659 611 
Aceview 962 944 1,316 590 
All genes identified using STAR 2,051 1,956 2,620 1,387 
All genes identified using TopHat2 1,763 1,717 2,569 911 
All differential genes 3,457 3,332 4,757 2,032 
Genes commonly altered in every  
STAR analysis 289 290 376 204 
Genes commonly altered in every  
TopHat2 analysis 333 342 381 294 
Final Stringent Gene List 88 80 108 60 
 
Table A-2: Overview of Statistical Results: Analysis Sets 1 and 2 are defined in more detail in 
the Supplementary methods section. Quant = Quantification, Stats = Statistics, Annot = 
Annotation 
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If the expression of a gene correlated with MAP within one group of subjects (either controls or 
hypertensive patients) or within both, the gene was considered a candidate regressor and 
included in the multivariate analysis. In contrast, if the expression of a gene only correlated with 
MAP in all subjects analyzed together, it was not included as a hypothetical regressor because it 
was assumed that such correlations reflect dichotomization of subjects by both blood pressure 
status and level of gene expression. RT-PCR data are represented as mean±SEM. Comparisons 
of characteristics between the normotensive and hypertensive groups were done with one-tailed 
Student’s t-Tests if data were normally distributed, with one-tailed Mann-Whitney tests if data 
were not normally distributed, or with chi-squares for categorical variables. A p-value <0.05 was 
considered significant. 
Results 
RNASeq analysis: The demographics of the 5 normotensive and 7 hypertensive subjects in the 
original cohort are given in Table A-1. The hypertensive patients had higher blood pressures 
despite treatment and slightly higher (albeit not statistically significant) body mass indices 
(BMI). The strict combinatorial analytical approach described in Methods (see online 
supplement) yielded a total of 60 transcripts in the monocytes isolated from these subjects that 
were identified as significantly differentially expressed after multiple-hypothesis correction (p 
value < 0.05; fold difference > 1.5) between normotensive and hypertensive groups (Table A-2). 
These 60 transcripts along with their fold-difference and p-values are shown in Table A-3. A 
positive fold-difference indicates the gene is upregulated in hypertensive individuals, and a 
negative fold-difference indicates the gene is downregulated in hypertensive individuals.  
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Symbol Gene Name p value FD 
ABCA13 
ATP-binding cassette, sub-family A (ABC1), 
member 13 7.0 X 10-03 48.2 
SLPI secretory leukocyte peptidase inhibitor  1.0 X 10-02 18.1 
TCN1 
transcobalamin I (vitamin B12 binding protein, R 
binder family)  7.2 X 10-03 12.7 
DEFA4 defensin, alpha 4, corticostatin 1.7 X 10-02 11.3 
CEACAM8 
carcinoembryonic antigen-related cell adhesion 
molecule 8 8.8 X 10-03 11.2 
CEACAM6 
carcinoembryonic antigen-related cell adhesion 
molecule 6 (non-specific cross reacting antigen) 1.2 X 10-02 10.9 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 1.2 X 10-02 10.5 
LCN2 lipocalin 2  8.2 X 10-03 10.1 
MMP8 matrix metallopeptidase 8 (neutrophil collagenase)  4.1 X 10-03 10.0 
CCL4 chemokine (C-C motif) ligand 4 8.4 X 10-03 9.6 
ATP2C2 ATPase, Ca++ transporting, type 2C, member 2 1.2 X 10-02 9.3 
MKI67 marker of proliferation Ki-67 1.2 X 10-02 9.0 
ARG1 arginase 1 8.6 X 10-03 8.7 
LTF lactotransferrin 5.0 X 10-03 8.6 
HJURP Holliday junction recognition protein  1.1 X 10-02 8.4 
CEACAM1 
carcinoembryonic antigen-related cell adhesion 
molecule 1 (biliary glycoprotein)  1.4 X 10-02 8.3 
PGLYRP1 peptidoglycan recognition protein 1  6.1 X 10-03 8.2 
RPL9 
 
 
ribosomal protein L9 1.3 X 10-03 8.2 
CAMP cathelicidin antimicrobial peptide 3.7 X 10-03 7.5 
RORA RAR-related orphan receptor A 1.1 X 10-02 7.5 
CRISP3 cysteine-rich secretory protein 3 7.4 X 10-03 6.6 
FAM20A family with sequence similarity 20, member A 2.7 X 10-03 6.3 
PDZD4 PDZ domain containing 4 1.9 X 10-03 6.0 
SAMD3 sterile alpha motif domain containing 3  2.4 X 10-03 5.9 
IL18RAP interleukin 18 receptor accessory protein 6.5 X 10-03 5.7 
SH2D1A SH2 domain containing 1A  8.4 X 10-03 5.5 
PTGDR prostaglandin D2 receptor (DP)  3.4 X 10-03 5.4 
CD247 CD247 molecule 1.4 X 10-02 5.4 
GZMH granzyme H (cathepsin G-like 2, protein h-CCPX)  3.7 X 10-02 5.3 
PTGES prostaglandin E synthase 1.3 X 10-02 4.8 
AFAP1 actin filament associated protein 1 1.6 X 10-03 4.6 
OLR1 
oxidized low density lipoprotein (lectin-like) receptor 
1  1.7 X 10-02 4.4 
HS3ST3B1 
heparan sulfate (glucosamine) 3-O-sulfotransferase 
3B1 7.9 X 10-03 4.3 
NKG7 natural killer cell granule protein 7  1.6 X 10-02 4.1 
MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa 6.8 X 10-03 4.1 
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gelatinase, 92kDa type IV collagenase)  
CCL3 chemokine (C-C motif) ligand 3 8.8 X 10-03 4.0 
RASGRP1 
RAS guanyl releasing protein 1 (calcium and DAG-
regulated)  5.5 X 10-03 3.8 
TNF tumor necrosis factor  3.2 X 10-03 3.1 
ANKRD33B ankyrin repeat domain 33B 1.5 X 10-03 2.4 
NFKBIZ 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, zeta 6.0 X 10-03 2.3 
MMRN1 multimerin 1  1.6 X 10-02 2.3 
CXCR1 chemokine (C-X-C motif) receptor 1 1.9 X 10-02 2.3 
NFKBIA 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha 2.7 X 10-03 2.2 
CPNE5 copine V  1.6 X 10-02 2.0 
CETP cholesteryl ester transfer protein, plasma 2.5 X 10-02 2.0 
FCHO2 FCH domain only 2 1.2 X 10-04 1.9 
MS4A4A 
membrane-spanning 4-domains, subfamily A, 
member 4A 2.5 X 10-03 1.8 
MCTP2 multiple C2 domains, transmembrane 2  1.0 X 10-03 1.8 
JAK3 Janus kinase 3 1.0 X 10-03 1.7 
B4GALT5 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 5 9.8 X 10-03 1.6 
GPRIN3 GPRIN family member 3 9.0 X 10-03 1.6 
FHL1 four and a half LIM domains 1 5.5 X 10-03 1.6 
CR1 
complement component (3b/4b) receptor 1 (Knops 
blood group)  2.2 X 10-02 1.5 
FCER1A 
Fc fragment of IgE, high affinity I, receptor for; alpha 
polypeptide  1.3 X 10-02 -1.6 
PID1 phosphotyrosine interaction domain containing 1  9.9 X 10-03 -1.6 
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 3.0 X 10-03 -1.6 
FLT3 fms-related tyrosine kinase 3 1.6 X 10-02 -1.7 
TNFRSF12A 
tumor necrosis factor receptor superfamily, member 
12A  2.0 X 10-02 -1.8 
VSIG4 V-set and immunoglobulin domain containing 4  5.4 X 10-03 -1.9 
ACCS 
1-aminocyclopropane-1-carboxylate synthase 
homolog (Arabidopsis)(non-functional) 4.0 X 10-03 -2.1 
 
Table A-3: List of the 60 Significant Genes and their fold-change: P value = average p value 
across 12 analyses, including Cuffdiff with multiple hypothesis correction. FD = average fold- 
difference across all 12 analyses, after conversion of Cuffdiff log2 values to fold-difference 
values. A positive fold-difference indicates the gene is upregulated in hypertensive individuals 
and a negative fold-difference indicates the gene is downregulated in hypertensive individuals.  
 
 
 102 
Hierarchical clustering (Figure A-1A) and Principal Components Analysis (PCA, Figure A-1B) 
of the 60 most robust genes demonstrated that the combined expression profile was sufficient to 
differentiate hypertensive from normotensive subjects.To identify known and predicted protein-
protein interactions among the 60 significantly altered genes, we employed the online network 
analysis tool, STRING v10 [152, 153], which yielded a large and multi-connected network of 
differentially expressed genes and inferred transcriptional regulators (Figure A-1C).     
Upstream regulatory analysis using Ingenuity Pathway Analysis (IPA) inferred activation of NF-
κB, IL-1β, and the adaptor protein myeloid differentiation primary response 88 (MYD88). These 
three molecules were predicted to be activated and are all part of the IL-1β signaling pathway 
that culminates in regulation of 21 of the 60 differentially expressed genes identified by RNASeq 
(Figure A-2). We also employed IPA to identify non-biased and significantly enriched functions 
in these 60 genes. The most statistically enriched disorder was “Inflammatory Response”, with a 
p value range of 5.4 X 10-4 to 4.6 X 10-15 (Table A-4), which essentially indicates a very low 
probability that this functional category would be represented by a significant portion of 60 
randomly selected genes. Based on causal prediction analysis, which uses individual 
relationships curated from the literature to infer functional directionality from transcriptional 
directionality (i.e., up- or down-regulation of each functionally related gene), the functions 
associated with inflammatory responses were activated (Z score= 2.595 to 2.943). Enriched 
molecular and cellular functions include immune cell migration and signaling, phagocytosis, 
proliferation of vascular smooth muscle cells, and T cell development (Table A-4).  
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Figure A-1: Genes from normotensive and hypertensive monocytes are different by 
RNAseq Analysis: (A) Hierarchical clustering of normalized RPKM (reads per kilobase per 
million mapped reads) for those genes that were identified as significantly differentially 
expressed using RNASeq. Intensity of red or green is used to show fold increase or decrease, 
respectively. Columns represent individual samples, and each row represents one gene. (B) 
Principal components analysis (PCA) of the 60 significant genes. Three components were 
sufficient to describe 80.6% of the variability among samples (48.8%, 20.2%, and 11.6% on the 
X, Y, and Z axes, respectively). (C) Protein network produced using the online analysis tool 
STRING v10. Analysis included the 60 significantly altered transcripts and most significant 
predicted regulators. Unconnected entities were removed, resulting in the network shown. 
Thickness of lines represent level of confidence (thicker = higher confidence).        
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Figure A-2. Functional Protein Network: Functional network generated from upstream 
regulator analysis using Ingenuity Pathway Analysis (IPA) software. The three central proteins 
were predicted to be activate using IPA (p values = 1.5 X 10-11 to 1.5 X 10-9, Z scores = 2.9 to 
3.9). Peripheral genes are overlaid with RNASeq expression values. Red or green color 
represents up- or down-regulation, respectively. Intensity of the color represents the degree of 
change. Orange lines with arrows indicate that directionality of the downstream gene is 
consistent with predicted activation of the up-stream regulator. Yellow lines indicate inconsistent 
results between gene expression and IPA’s knowledge base for that particular interaction. Gray 
lines indicate that directionality cannot be resolved.    
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Top Diseases and Bio Functions Enrichment Predicted Activation p value  No. *Z score Direction 
DISEASES AND DISORDERS 
Inflammatory Response 5.4 X 10-4 – 4.6 X 10-15 33 NA 
Activation of leukocytes 4.6 X 10-15 22 2.943 Activated 
Inflammatory response 4.2 X 10-13 21 2.670 Activated 
Activation of myeloid cells 7.5 X 10-13 15 2.685 Activated 
Activation of phagocytes 2.5 X 10-12 15 2.569 Activated 
Activation of macrophages 2.0 X 10-11 12 2.595 Activated 
MOLECULAR AND CELLULAR FUNCTIONS 
Cellular Movement 5.8 X 10-4 – 4.4 X 10-16 32 NA 
Cell movement of mononuclear 
leukocytes 
6.5 X 10-12 16 2.975 Activated 
Cell movement of lymphocytes 9.7 X 10-11 14 2.802 Activated 
Migration of cells 1.0 X 10-10 28 2.668 Activated 
Cell movement of monocytes 5.9 X 10-8 8 2.740 Activated 
Migration of mononuclear 
leukocytes 
7.0 X 10-8 11 2.823 Activated 
Cell-cell Signaling and 
Interaction 
5.5 X 10-4 – 4.6 X 10-16 30 NA 
Cellular Function and 
Maintenance 
5.5 X 10-4 – 4.0 X 10-10 28 NA 
Engulfment of cells 1.7 X 10-6 10 2.649 Activated 
Phagocytosis of cells 3.7 X 10-5 7 2.050 Activated 
Cellular Development 5.7 X 10-4 – 1.5 X 10-9 29   
Proliferation of smooth muscle 
cells 
5.7 X 10-5 7 2.006 Activated 
Proliferation of vascular smooth 
muscle cells 
1.4 X 10-4 5 2.173 Activated 
Development of lymphocytes 2.2 X 10-4 9 2.264 Activated 
T cell development 5.5 X 10-4 8 2.609 Activated 
PHYSIOLOGICAL SYSTEM DEVELOPMENT AND FUNCTION 
Immune Cell Trafficking 5.6 X 10-4 – 4.4 X 10-16 30 NA 
Hematological Dev/Function 5.8 X 10-4 – 2.7 X 10-15 31 NA 
Tissue Morphology 5.8 X 10-4 – 8.4 X 10-10 27 NA 
Quantity of CD4+ T-lymphocytes  1.2 X 10-5 6 2.200 Activated 
 
Table A-4: Functional Analysis of Significant Genes: Main functional categories shown in 
bold, Sub-categories are italicized. *Positive and negative Z scores of >2.0 are generally 
considered as significant for activation and inhibition, respectively. 
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Regression Analysis of Gene Determinants of Blood Pressure: The expression (log10 normalized 
RPKM; reads per kilobase per million mapped reads) of 15 genes (ABCA13, ARG1, cAMP, 
CEACAM1, CEACAM8, CHI3L1, CRISP3, LCN2, LTF, MMP8, OLR1, PGLYRP1, PTGES, 
SLPI, and TCN1) correlated significantly with mean arterial pressure (MAP) within the group of 
normotensive controls (r=0.91 to 0.99) and among all patients together (r=0.65 to 0.79), whereas 
that of three additional genes (FAM20A, MMP9 and FCER1A) correlated significantly within 
the controls only (r=0.89 to 0.97). By multivariate regression, only LTF and PGLYRP1 remained 
significant predictors of MAP variability in normotensive controls.  
The expression of 4 genes (CD247, GZMH, PDZD4 and PTGDR) correlated significantly with 
MAP within the hypertensive subjects (r=0.77 to 0.88) and among all patients together (r=0.70 to 
0.80). By multivariate regression, the only significant predictor of MAP variability in 
hypertensive subjects was GZMH.  
The expression of IL18RAP correlated significantly with MAP of controls (r=0.93), hypertensive 
patients (r=0.78) and of all subjects analyzed together (0.89). By multivariate regression, the 
expression of this gene was the only significant determinant of MAP in all subjects.  
The univariate correlations for the four significant genes in multivariate analyses are shown in 
Figure A-3. The corresponding models for MAP based on expression of these genes are shown 
in Table A-5. 
Quantitative RT-PCR in the validation cohort: The demographics of these 6 normotensive and 9 
hypertensive subjects are given in (Table A-6). Blood pressures and BMI were slightly but not 
significantly higher in hypertensives compared to normotensives.  
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Figure A-3: Regression Analyses of MAP from Genes that were Significant Predictors: 
Univariate regressions of mean arterial pressure (MAP) on the expression (log(10)RPKMs) of 
those genes that were significant predictors of MAP in multivariate regression analyses: (A) 
lactotransferrin, LTF, (B) peptidoglycan recognition protein 1, PGLYRP1, (C) granzyme H, 
GZMH and (D) interleukin 18 receptor accessory protein, IL18RAP. Control normotensive 
subjects are represented by open dots, and hypertensive patients are shown by closed dots. 
Pearson correlation coefficients and their significance are given for controls (C, n=5), 
hypertensive subjects (HTN, n=7) or all subjects analyzed together (All, n=12). P<0.05 was 
considered significant. 
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Gene Group Model R2 p-value 
LTF and 
PGLYRP1 
C MAP = 60.01 (±0.41) + 14.60 (±0.53)*log10LTF 
+ 4.54 (±0.59)*log10PGLYRP1 
0.99 p<0.0001 
GZMH H MAP = 98.45 (±2.60) + 24.28 
(±5.86)*log10GZMH 
0.77 p<0.009 
IL18RAP All MAP = 99.15 (±2.50) + 26.75 
(±4.42)*log10IL18RAP 
0.79 p<0.0002 
 
Table A-5: Multivariate Regression Models for MAP using expression levels of LTF, 
PGLYRP1, GZMH, and/or IL18RAP: C = normotensive controls, H = hypertensive patients, 
All = all subjects analyzed together 
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 Normotensive  
Controls (n=6) 
Hypertensive 
Patients (n=9) 
p value 
Age (years) 42.2±6.3 50.4±3.2  
Sex (F/M) 3/3 7/2  
Race (W/B/A) 4/1/1 7/2/0  
Duration of HTN (years) NA 15.0±3.8  
Systolic BP (mmHg) 128.0±5.5 140.4±8.9  
Diastolic BP (mmHg) 72.7±3.0 78.3±2.5  
MAP (mmHg) 91.1±3.1 99.0±4.3  
BMI (kg/m2) 25.7±2.6 30.2±2.4  
Antihypertensive Drugs:    
None  1  
TZ + TMT  2  
CCB + α1B  1  
CCB + SP  1  
ACEi  2  
ACEi + TZ  1  
ARB + TZ + CCB  1  
 
Table A-6: Demographics Table for Validation Cohort: n = number of subjects in each group, 
HTN = hypertension, BP = blood pressure, MAP = mean arterial pressure, BMI = body mass 
index. TZ=thiazide diuretics; TMT=triamterene; CCB=dihydropyridine calcium channel 
blockers; α1B=peripheral alpha-1 adrenergic receptor blockers; SP=spironolactone; 
ACEi=angiotensin converting enzyme inhibitors; ARB=angiotensin AT1 receptor blockers. 
Unpaired t-test and chi-square comparisons were performed between groups. Lack of a p value 
in the rightmost column indicates lack of statistical significance. 
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Frequency and type of antihypertensive treatment was slightly different from the original cohort. 
We examined 8 of the 60 genes by quantitative RT-PCR (qPCR): 4 were the ones that we found 
to predict MAP in multivariate models (Figure A-3) and the other 4 were chosen due to known 
or predicted effects on inflammation (ARG1, CCL4, MMP8, and VSIG4). Six out of these 8 
genes were significantly altered in the predicted direction (with GZMH showing a trend but not 
reaching statistical significance), demonstrating that our findings are robust and reproducible 
(Figure A-4 and Figure A-5). 
Discussion 
Despite conventional treatment, hypertension remains uncontrolled in nearly 50% of patients 
with the disease [108]. Even when blood pressure is relatively controlled, hypertensive patients 
are still at an elevated risk of cardiovascular events [116, 117]. This suggests that the risk of the 
hypertensive process may be due to factors other than blood pressure, which are insufficiently 
addressed by current pharmacological therapy. Our study suggests that altered monocyte 
function, reflected by altered gene expression, may be at least partly responsible for the residual 
cardiovascular risk in patients with hypertension. Using RNAseq, we identified 60 RNA 
transcripts that are differentially expressed between monocytes from normotensive versus treated 
hypertensive subjects. We chose 8 of these genes to validate by qPCR in a separate cohort of 
normotensive and hypertensive subjects. Remarkably, we were able to validate the predicted 
changes in 6 of the 8 genes tested despite the fact that the two cohorts differed in their anti-
hypertensive medication profile. Multivariate regression analyses revealed that 2 genes (LTF and 
PGLYRP1) significantly correlated with MAP in control subjects and thus may be involved in 
blood pressure homeostasis. One gene, GZMH, significantly correlated with MAP only in 
hypertensive subjects and thus may be a marker of injury in hypertension. 
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Figure A-4: RT-PCR for selected genes in the validation cohort: Relative PCR quantification 
(normalized to GAPDH) of (A) lactotransferrin, LTF (B) peptidoglycan recognition protein 1, 
PGLYRP1 (C) interleukin 18 receptor accessory protein, IL18RAP (D) arginase 1, ARG1 (E) 
matrix metalloproteinase 8, MMP8 and (F) V-set and Ig domain-containing 4, VSIG4 in a new 
cohort of normotensive (n=6) and hypertensive (n=9) patients. Data are plotted as mean±SEM. 
*P<0.05. 
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Figure A-5: Genes non-significant by RT-PCR in the validation cohort: Relative PCR 
quantification (normalized to GAPDH) of (A) granzyme H, GZMH and (B) chemokine (C-C 
motif) ligand 4, CCL4 in a new cohort of normotensive (n=6) and hypertensive (n=9) patients. 
Data are plotted as mean±SEM. *P<0.05. 
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Of note, IL18RAP significantly correlated with MAP within normotensive and hypertensive 
subjects and in all subjects combined. We were able to develop a putative model for monocyte 
activation and signaling in hypertension using several of the molecules identified through 
RNAseq, regression analyses, qPCR validation, and inferred through systems biology 
approaches and the literature (Figure A-6).  
Interestingly, 21 of the 60 genes identified are downstream of the IL-1β pathway. IL18RAP (also 
known as IL18Rα) binds to the IL18 receptor and enhances IL18 signaling [154]. Both IL-1β 
and IL18 are products of the inflammasome, a multimeric protein complex important in innate 
immunity (Figure A-6). There is emerging evidence that the inflammasome and its products also 
play a critical role in hypertension [154, 155]. The inflammasome is activated by damage 
associated molecular pattern receptors (DAMPs) and pathogen associated molecular pattern 
receptors (PAMPs) that bind to toll-like receptors and signal through NFκB. The exact DAMP or 
PAMP that activates the inflammasome in hypertension is unknown. While one would speculate 
that a DAMP might contribute to immune activation in hypertension, our results suggest that the 
PAMP, peptidoglycan recognition protein 1 (PGLYRP1), might play an important role. 
PGLYRP1 binds to triggering receptor expressed on myeloid cells (TREM)-1 either as a 
complex with bacterial peptidoglycan or in the absence of bacterial peptidoglycan when it is 
multimerized [156]. Signaling through TREM-1 results in activation of NFκB and NFAT 
mediated transcription (Figure 4). Interestingly, PGLYRP1 has been implicated in reactive 
oxygen species (ROS) formation in neutrophils [157]. Since hypertensive monocytes express 
more isoketals, a by-product of oxidative injury [34], it is attractive to hypothesize that 
PGLYRP1 is upstream of ROS production in monocytes.  
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Figure A-6: Schematic of monocyte signaling pathway identified: Putative monocyte 
signaling pathway produced using ePath3D (Protein Lounge) based on study analysis results and 
review of the literature. Type of evidence and source for each molecule are listed in tabular form 
at the bottom of the figure.   
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Notably, Rohatgi et al [158] showed that increased PGLYRP1 levels are associated with all 
major cardiovascular risk factors (including hypertension), with inflammatory markers such as 
C-reactive protein and interleukin 18, and with coronary artery calcium, aortic wall thickness, 
and abdominal aortic plaque burden.   
Other genes that we validated by qPCR or that we found to correlate with MAP in regression 
analyses that are particularly interesting include lactotransferrin (LTF), arginase 1 (ARG1) and 
V-set and immunoglobulin domain containing 4 (VSIG4). Recombinant human LTF induces 
maturation of human monocyte-derived dendritic cells, leading to up-regulation of HLA class II, 
CD83, CD80 and CD86 costimulatory molecules, and CXCR4 and CCR7 chemokine receptors 
[159].  ARG1 is involved in the metabolism of arginine to urea and ornithine which is involved 
in wound healing. Increased ARG1 activity theoretically depletes arginine and thus could reduce 
nitric oxide synthesis by the nitric oxide synthases (Figure A-6). While ARG1 is a marker of 
alternatively activated M2 macrophages in mice, this is not necessarily true in humans [160]. The 
role of ARG1 in hypertensive monocytes requires further study. VSIG4 is one of the few genes 
that was down-regulated in hypertensive monocytes. VSIG4 is a B7 family-related protein that 
has been shown to function as a negative regulator of T cell activation [161]. Thus, the 
downregulation of VSIG4 could therefore promote T cell activation and cytokine production in 
hypertension. 
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